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ABSTRACT
Association Between Latent Toxoplasma gondii Infection and Alzheimer's Disease
Cynthia Elizabeth Wyman
Department of Psychology, BYU
Doctor of Philosophy
Many studies have found an association between Toxoplasma gondii seropositivity and
behavioral and cognitive changes in animal models and in humans. In addition, early findings
have suggested an association between T. gondii seropositivity and Alzheimer’s disease (AD).
This work sought to determine whether there is an association between T. gondii seropositivity
and AD as well as cognitive functioning (including memory, working memory, processing
speed, language functioning, executive functioning) in a large, well-characterized sample of
subjects with AD and matched controls without dementia. Using enzyme-linked immunosorbent
assay (ELISA) assays, anti-T. gondii IgG antibody titers were determined in 114 control subjects
and in 105 subjects diagnosed with AD through an Alzheimer’s Disease Research Center. The
seroprevalence between the two groups were compared using propensity score matching (PSM).
Associations between T. gondii seropositivity and cognitive functioning were also compared
using both PSM and linear regressions. No differences were found between groups in age,
ethnicity, or gender. Education and socioeconomic status was slightly higher in the control
group. Using PSM, no significant differences were found in having AD due to T. gondii
seropositivity between the two groups. Using PSM, T. gondii seropositivity was associated with
worse performance on the WAIS-R Digit Symbol test. Within the AD group, T. gondii
seropositivity was associated with worse performance on the WAIS Block Design and Trail
Making B tests. In this sample, no evidence of an association between T. gondii seropositivity
and AD was found in a larger study than previous studies. However, evidence of a negative
association between processing speed and T. gondii seropositivity as well as a negative
association between processing speed, executive functioning, and T. gondii seropositivity in
those with AD was found.

Keywords: Toxoplasma gondii, Toxoplasmosis, Alzheimer disease, neurocognitive function,
aging, processing speed, executive function
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Association Between Latent Toxoplasma gondii Infection and Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common form of dementia, the most common
neurodegenerative disorder, and an estimated 5.4 million Americans had AD in 2012 (Gu et al.,
2017). The disease causes progressive brain deterioration and is characterized by marked
cognitive decline (Alzheimer's Association, 2013). AD is a growing public-health concern and is
the sixth leading cause of death in the United States. A variety of factors are associated with the
development of AD including neurological changes such as the well-known accumulation of
beta-amyloid and tau proteins, genetic mutations (such as in the presenilin and ApoE genes),
family history, environmental stress, illiteracy or lack of early education, physical activity,
cognitive activity, social activity, nutrition, and cardiovascular risks (Polidori, Nelles, & Pientka,
2010). Additionally, there is growing interest in the role of infectious diseases, including
parasites, and their impact on development of AD as well as cognitive function. For example,
Katan, Moon, Wright, and Elkind (2013) found an association between a history of exposure to
bacterial and viral pathogens and cognitive function. Other studies show an association between
the protozoal parasite Toxoplasma gondii and cognitive, behavioral, and neurological changes in
human and animal models, making the parasite a possible factor in the development of cognitive
decline and AD (Dalimi & Abdoli, 2012; Fekadu, Shibre, & Cleare, 2010).
Toxoplasma gondii
Toxoplasma gondii is a common parasite that has particular affinity for the central
nervous system (CNS) in intermediate hosts. Felines are the definitive host (the host in which
the parasite sexually replicates) for T. gondii and intermediate hosts (hosts in which the parasite
is metabolically active, lives, and reproduces through asexual cell division) include almost all
warm-blooded animals including humans (Fekadu et al., 2010; Gulinello et al., 2010). Although
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humans are not the definitive hosts of T. gondii, prevalence rates for IgG seropositivity (having
IgG antibodies to T. gondii after the acute stage of the infection) in humans are surprisingly high.
Worldwide prevalence is reported to be between 30 to 50 percent (Carter, 2013; Hermes et al.,
2008). In some parts of the world, the seroprevalence (prevalence of those seropositive for the
parasite) rates can be as high as 80 percent (Dalimi & Abdoli, 2012). In the United States, the
seroprevalence rates tend to be lower than the worldwide prevalence for adults, ranging from
approximately nine to 22 percent (Dubey & Jones, 2008; Montoya & Liesenfeld, 2004).
Additionally, prevalence rates in age groups older than 40 to 49 years tend to be higher than
those of younger age. One study found prevalence in those over 70 years as high as 42 percent
(Jones et al., 2001).
T. gondii infection of humans by oocysts and cysts can happen through vertical
transmission (from a woman to her child during or after birth), eating undercooked meat infected
with Toxoplasma cysts, or contaminated food or water that contains oocysts 1, or handling soil
contaminated with oocysts (Kannan & Pletnikov, 2012). Thus, transmission of the parasite need
not involve the definitive host at all, as ingesting cysts from the parasite can transmit the parasite
to another host. After ingestion of the parasite, the acute phase of disease consists of
tachyzoites 2 proliferating in any nucleated cell in the body and destroying the host cell in the
process. After the acute phase, the second stage consists of bradyzoite 3 tissue cysts in skeletal
muscle and the brain, including cysts in astrocytes, microglia, and neurons (Fabiani, Pinto,
Bonuccelli, & Bruschi, 2015; Fekadu et al., 2010). These cysts can become dormant and are
1

Oocysts are cysts containing zygotes.

2

Tachyzoites are part of the asexual stage of rapid growth of T. gondii.

3

Bradyzoites are the slowly multiplying, encysted form of T. gondii.
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characteristic of chronic, or latent, infection, which is lifelong and can cause continuous infection
of the brain as well as persistent seropositivity for the parasite (Dalimi & Abdoli, 2012; Fekadu
et al., 2010; Kannan & Pletnikov, 2012; Prandovszky et al., 2011). All infected humans develop
an acute immune reaction to T. gondii, and then if the person is not immunocompromised, the
infection most often becomes dormant. Development of an immune response (seropositivity)
can provide life-long immunity against toxoplasmosis (Jung et al., 2012). However, T. gondii
infection can be reactivated if host immunity wanes. Feline infection results in the production of
oocysts by the parasite, which are then excreted into the environment and can be transmitted to
other organisms (Kannan & Pletnikov, 2012). Sexual reproduction of the parasite can only
happen in felines, but asexual reproduction can occur in any infected animal, including humans.
Certain risk factors are associated with developing T. gondii seropositivity humans,
which are often dependent on the region of the world examined. In the United States, increasing
age and lower levels of education are associated with T. gondii seropositivity. In addition,
Hispanic ethnicity and ethnicity reported as “other” have statistically higher seroprevalence than
non-Hispanic whites (Gale, Brown, Erickson, Berrett, & Hedges, 2014). Additionally, Mexican
Americans and non-Hispanic black persons also tend to have a higher seroprevalence.
Seroprevalence also tends to vary based on region in the United States. The northeastern United
States has a seroprevalence rate of 29.2 percent, the south at 22.8 percent, the midwest at 20.5
percent, and the west with the lowest rate at 17.5 percent. Lastly, other risk factors for
developing T. gondii seropositivity in the United States include living in a crowded conditions,
being foreign-born, and working in soil-related jobs (Dubey & Jones, 2008). A study from
Mexico found T. gondii seropositivity is associated with having no formal education, female
gender, presence of dogs at home, eating raw dried meat, and eating goat, turkey, and pigeon
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meat. Additionally, those who raised animals also had a higher rate of T. gondii seropositivity
than those who did not (Alvarado-Esquivel et al., 2014). Why these risk factors are related to T.
gondii seropositivity is unclear but various hypotheses have been proposed, including
undercooking of meat before eating, poor sanitation, soil-related occupation, and crowded
households (Alvarado-esquivel et al., 2014; Pearce, Kruszon-moran, & Jones, 2014).
In immunocompetent humans, most infections with T. gondii result in T. gondii
seropositivity, a chronic, asymptomatic, latent infection in the brain, rather than an acute
infection. The most replicated association with T. gondii seropositivity is schizophrenia, with
over 38 studies finding an association between T. gondii seropositivity and schizophrenia
(Webster, Kaushik, Bristow, & Mcconkey, 2013). Other associations include depression, bipolar
disorder, obsessive-compulsive disorder, suicide attempts, lower IQ scores, Parkinson’s disease,
epilepsy, and intellectual disability, but these associations have not be studied thoroughly or
consistently replicated (Dalimi & Abdoli, 2012; Fekadu et al., 2010).
Potential Connections Between AD and T. gondii
In addition to the other diseases listed above, a few studies show an association between
T. gondii seropositivity and AD (Dalimi & Abdoli, 2012; Flegr, Lenchova, Hodny, & Vondrova,
2011). Kusbeci, Miman, Yaman, Aktepe, and Yazar (2011) found a significantly increased
prevalence of T. gondii seropositivity of anti-T. gondii IgG antibodies in individuals with
Alzheimer’s disease as compared to control groups (44.1% and 24.3% respectively, p = 0.005) in
a sample size of 71. Another study by Rashno, Fallahi, and Bahrami (2017) examined 87 adults
with AD and 87 healthy controls for T. gondii seropositivity. In this study, they did not find an
association between T. gondii seropositivity and AD (Rashno et al., 2017). In addition, Mahamioskouei et al. (2016) examined 75 patients with AD and 75 healthy controls and again found no
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association between AD and T. gondii seropositivity. Thus, the evidence of association between
AD and T. gondii seropositivity based on seroprevalence between AD groups and healthy
controls is mixed and more evidence is needed. Two lines of evidence support the possibility of
T. gondii seropositivity as a factor contributing to the development of AD, specifically cognitive
changes (and accompanying behavioral changes) associated with T. gondii infection and the
pathology of T. gondii in its latent form of cysts in the human brain.
Cognitive Changes Associated with T. gondii
Some studies found overall cognitive changes in T. gondii seropositive humans and mice.
For example, Kannan and Pletnikov (2012) report T. gondii seropositive young adult men had
lower verbal intelligence compared to age-matched uninfected controls. Additionally, Ibrahim et
al. (2016) found higher anti-T. gondii IgG antibody titers are associated with worse accuracy on
a line orientation test, measured emotion differentiation test, and emotion recognition test.
Importantly, not all associations between T. gondii seropositivity and cognition indicate a
negative effect on cognition. Some studies found a positive association between T. gondii
seropositivity and some cognitive measures. For example, Ibrahim et al. (2016) found those with
higher anti-T. gondii IgG antibody titers had faster reaction times on the Penn Conditional
Exclusion Test.
Cognition can be defined many ways, but it is often defined by placing different
cognitive abilities into various cognitive domains. In particular, neuropsychological tests (which
are often used to assess cognition in humans) can divide into the following domains: memory
(including working memory), processing speed, language functioning, executive functioning,
and visuospatial abilities (Nuechterlein et al., 2004; Sheline et al., 2006). We will discuss these
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domains expect visuospatial abilities with relevance to their association with T. gondii
seropositivity, in both human and mouse studies, and for both positive and negative effects on
cognition.
Memory and working memory – Mouse studies. The results from mouse models
examining memory and T. gondii infection are mixed. Some studies show impaired recognition
memory for chronically infected (six to nine weeks post infection), while other studies show no
impairment (Kannan & Pletnikov, 2012). For example, Gulinello et al. (2010) found normal
spatial memory, levels of novel object exploration, recognition memory, and familiar object
exploration in chronically infected (seven weeks post infection) mice. However, Mahmoudvand
et al. (2016) infected mice with T. gondii and found that T. gondii IgG seropositive mice had
impaired learning and spatial memory functions compared to control mice as tested by the
Morris water maze. In addition, the authors also infected mice with AD pathology with
Toxoplasmosis. Again, using the Morris water maze, the authors found that the mice with both
AD pathology and T. gondii IgG seropositivity had significantly more impairment in some
learning and memory functions (e.g. distance to reach the platform, escape latency) than only T.
gondii IgG seropositive mice and only AD pathology mice. In other areas of learning and
memory tasks, however, the T. gondii IgG seropositive and AD pathology mice performed
similarly to mice with only AD pathology. Lastly, the study found that T. gondii IgG
seropositivity led to the promotion of neuroinflammation as well as the progression of AD in
mice (Mahmoudvand et al., 2016).
Using the same study design as in Mahmoudvand et al. (2016), the authors examined the
effect of donepezil (an acetylcholinesterase inhibitor, often used in the treatment of AD) on
memory functioning in T. gondii IgG seropositive mice. T. gondii IgG seropositive mice had
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delayed learning (as measured by a longer distance traveled and longer time to reach the
platform in the Morris Water Maze). However, when the mice were treated with donepezil, the
mice had significantly reduced time and distance traveled to the platform compared to the
untreated, infected mice. Additionally, T. gondii IgG seropositive mice had longer escape
latency than uninfected mice. Again, when treated with donepezil, T. gondii IgG seropositive
mice had significantly shorter escape latency times than the untreated mice. As found
previously, T. gondii IgG seropositive mice had short-term memory impairment, which was
reversed by treatment with donepezil. Importantly, no differences were found in swimming
speed between any of the groups, indicating no differences in visual or motor abilities
(Mahmoudvand, Sheibani, Keshavarz, et al., 2016).
Another study used a Morris water maze to test infected mice’s spatial reference memory
by having them find a platform submerged in water (Daniels, Sestito, & Rouse, 2015). The
study found that infected mice demonstrated worse memory for the location of the platform after
it had been moved (as measured by the mice crossing the area where the platform used to be).
Additionally, the infected mice performed more poorly at finding the moved platform after
longer delays from the learning trial (e.g. two hours versus 24 hours). Three other studies found
similar impairment in spatial memory based on infected mice’s worse performance in maze
navigation. However, another study found no impairment in spatial memory in infected rats
(Worth, Thompson, & Lymbery, 2014).
In another study, infected mice showed impaired learning and memory as measured by a
two-way active avoidance equipment as compared to control mice and mice infected with the
parasite Toxocara canis. Interestingly, infected mice also showed increased anxiety as measured
by the elevated plus maze (Corrêa, Chieffi, Lescano, & Vieira, 2014).
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While not always part of conscious memory, studies often consider fear-conditioning
memory as a type of memory. Ihara et al. (2016) used a fear-conditioning task (pairing an
auditory cue with a foot shock) to determine if infected mice varied in their memory of feareliciting cues. Infected mice had significantly less freezing behavior when the auditory cue was
played (after the mice had been conditioned), suggesting reduced fear conditioning memory
(Ihara et al., 2016). Additionally, another study found impaired olfactory memory in infected
male mice (Worth et al., 2014). However, these findings of reduced fear conditioning and
olfactory memory have not been well-replicated by other studies.
Importantly, different strains of T. gondii may have different behavioral and cognitive
effects on mice. For example, Kannan et al. (2010) examined the Prugniaud and ME49 strains of
T. gondii and how they may affect mouse working memory. Mice IgG seropositive with the
ME49 strain showed impaired spatial working memory while IgG seropositive mice with the
Prugniaud strain did not. While some research has been performed on different strains in mice,
to our knowledge, no such research has been performed on T. gondii seropositivity in humans
and as such, these results need to be replicated in human studies.
In sum, most of the studies examining T. gondii infection in mice found impaired spatial,
short-term, and delayed memory in infected mice compared to control mice. These results show
replication by other studies with fewer studies in the literature finding no association between T.
gondii seropositivity and memory in mice. Interestingly, one study found mice with AD
pathology and T. gondii IgG seropositivity displayed significantly worse learning and memory
functioning in some tasks compared to mice with only AD pathology, but this study has yet to be
replicated. Thus, overall, infected mice seem to consistently show impairment in many areas of
memory functioning.
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Memory and working memory – Human studies. In humans, a study in school-aged
children examined T. gondii seropositivity and its effects on cognitive function, specifically
memory. A large study (n=1755), Mendy, Vieira, Albatineh, and Gasana (2015) found T. gondii
seropositive children had worse working memory and short-term memory skills (as measured by
the WISC-R Digit Span subtest) compared to seronegative children. The authors also found that
T. gondii seropositive children who also had serum vitamin E levels below the median had
significantly worse working memory and short-term memory scores than children with vitamin E
serum levels at or above the median.
At different stages in the lifespan, T. gondii seropositive young adult and elderly men had
greater impairment in delayed and immediate memory compared to controls (Kannan &
Pletnikov, 2012). In addition, T. gondii seropositive subjects performed worse on the N-back
neuropsychological test compared to seronegative controls. When the researchers adjusted the
scores for age and sex, however, the significance between scores was lost (Guenter, Bieliński,
Deptuła, & Zalas-więcek, 2012). Also, when Flegr, Guenter, Bieli, Deptuła, and Zalas-więcek
(2012) re-analyzed the data separately for males and females, T. gondii seropositive females
performed more poorly than did seronegative females on the N-back test.
Hamdani et al. (2017) examined the effect of exposure to many viruses and parasites
including T. gondii on memory functioning. The subjects with previous exposure to HSV-1,
HSV-2, CMV, and T. gondii had worse scores on a test of working memory (backward digit span
and letter number sequencing) than those without exposure to all four infectious agents.
However, the researchers did not find an association between exposure to only T. gondii and
memory functioning.
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While Gale, Erickson, Brown, and Hedges (2015) did not find a main effect for T. gondii
seropositivity on cognition in a large study (n= 1785), they did find that those seropositive for
both T. gondii and H. pylori had lower functioning on a serial-digit learning task (testing
working memory), suggesting that having more than one infectious disease may result in greater
loss of memory function than having just one infectious disease (Gale, Erickson, Brown, &
Hedges, 2015).
In a large study similar to the studies by Gale et al. (2014) and Gale, Erickson, Berrett,
Brown, and Hedges (2016), Pearce, Kruszon-Moran, and Jones (2014) found those T. gondii
seropositive had worse performance on the symbol-digit substitution test and the serial-digit
learning test, both measures of working memory (as well as processing speed), in models without
any adjustments made for covariates. When the researchers added age, race/ethnicity, gender,
and foreign birth to the models, those T. gondii seropositive were more likely to have symboldigit substitution test scores in the worst quartile. However, when the researchers added all the
covariates to the models (including life-style variables, demographic factors, and medical
conditions), the likelihood that T. gondii seropositive subjects would have worse scores was the
same as those who were seronegative. When the authors examined interactions between T.
gondii seropositivity and poverty level, however, for those in the lowest income category, T.
gondii seropositive subjects had worse performance on the symbol-digit substitution test even
after controlling for covariates. Additionally, those born outside the United States had worse
performance on the symbol-digit substitution test while controlling for covariates.
Older adults. Gajewski, Falkenstein, Hengstler, and Golka (2014) and Gajewski,
Falkenstein, Hengstler, and Golka (2016) examined working memory in older adults (mean age:
70 years) and found T. gondii seropositive older adults had lower scores on a verbal memory test
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(Verbal Learning and Memory Test) for both immediate memory and delayed recognition
portions. Additionally, seropositive older adults had lower performance on the Word Fluency
Test testing long-term semantic memory. On the N-back task, T. gondii seropositive older adults
performed more poorly, which is likely indicative of worse working memory. Interestingly, T.
gondii seropositive subjects with older age had worse performance on the verbal memory task,
which was not true for seronegative subjects (Gajewski et al., 2014, 2016).
In another study, Mendy, Vieira, Albatineh, and Gasana (2015) examined memory
functioning in a large sample of older adults (N=4485; 60 years and older) using the verbal
memory portion of the Mini Mental State Examination (MMSE) and the East Boston Memory
Test. They found that T. gondii seropositive older adults had associated decreased immediate
memory functioning but no associations for delayed memory. Additionally, the researchers
found higher serointensity of anti-T. gondii antibodies (a higher concentration of antibodies) was
negatively associated with immediate memory scores. Lastly, the authors found more significant
associations between T. gondii seropositivity and serointensity and worse immediate memory
scores in white Americans compared to other ethnicities (Mendy et al., 2015).
Overall, the most replicated results show T. gondii seropositivity seems to be associated
with working memory impairment in certain circumstances such as participants having other
infections (including H. pylori, HSV, CMV), being born outside the United States, and having
lower income. These interactions may be due to several factors. For example, having multiple
infections may result in increased inflammation which may reduce cognitive efficiency and/or
capacity. Additionally, lower incomes are often associated with lower educational levels, which
lower education levels may result in fewer neuronal connections allowing for more negative
impact from T. gondii on memory (Borroni, Premi, Bozzali, & Padovani, 2012). If true, high
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education may protect against the negative effects on memory of T. gondii seropositivity by
providing more neural connections and more neuronal paths for use in case some paths become
damaged by T. gondii. Overall, researchers tend to find no or few main effects for T. gondii
seropositivity on working memory for adults (Gale et al., 2015; Hamdani et al., 2017; Brad D
Pearce, Kruszon-Moran, & Jones, 2014). In older adults, more studies found main effects
associated with T. gondii seropositivity including decreased verbal memory (both immediate and
delayed), working memory, and long-term semantic memory (Gajewski et al., 2014, 2016).
Increasing age may amplify the influence T. gondii seropositivity has on cognition, making main
effects more common in studies of older adults. However, the studies for older adults tend to
have much smaller sample sizes than the studies performed on middle-age or younger adults.
The few studies performed in children examining T. gondii seropositivity and memory
functioning have not been consistently replicated.
Processing speed. In a large, community-based sample (n=4178), Gale et al. (2014) did
not find a correlation between T. gondii seropositivity and cognitive functioning (specifically for
a test of processing speed with attention and short-term memory components) for adults between
the ages of 20-59 years. While no main effects were found, the authors did see an association
between T. gondii seropositivity and decreased processing speed among non-Hispanic Blacks
and other race-ethnicities when compared to non-Hispanic Whites. Additionally, the study found
having low levels of education was associated with worse processing speed. They also found
those subjects who were T. gondii seropositive and had a lower poverty-to-income ratio
(meaning closer to the official United States poverty threshold) also had slower processing
speed.
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In addition to working memory, the previously-mentioned study by Pearce et al. (2014)
examined processing speed using the Simple Reaction Time Test. Like their findings with
working memory, those T. gondii seropositive had slower reaction times than those seronegative.
However, when the researchers added all covariates to the model, they did not find any
significant differences between those T. gondii seropositive or seronegative (Pearce et al., 2014).
In another study by Pearce et al. (2013), researchers measured acoustic startle response
latency in both subjects with schizophrenia and controls in order to measure neural processing
speed. The study found larger acoustic startle latency (indicating slower processing speed) for T.
gondii seropositive subjects in both subjects with schizophrenia and controls. These findings
may reflect similar findings of slowed psychomotor speed in T. gondii seropositive mice (Pearce
et al., 2013).
Massa et al. (2016) measured the acoustic startle response in a sample of mostly African
Americans that included subjects with and without psychiatric disorders, such as MDD and
schizophrenia. The authors indicate that acoustic startle response is an index of early
information processing ability. They found a larger acoustic startle response for those T. gondii
seropositive, even when adjusting for psychiatric illness and demographic factors, indicating
those T. gondii seropositive had slower early information processing (Massa et al., 2016).
Fewer studies have been performed examining processing speed and T. gondii
seropositivity than for memory functioning. Overall, the findings seem to be mixed in terms of
main effects of T. gondii seropositivity. Some studies (particularly those with larger sample
sizes) have not found a main effect for T. gondii seropositivity on processing speed but have
found certain circumstances that seem to interact with T. gondii seropositivity to effect
processing speed, specifically ethnicity, lower levels of education, and lower income (Gale et al.,
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2014; Pearce et al., 2014). As with the memory studies, some of the interaction effects seen in
studies may again be due to a larger cognitive reserve for those with higher levels of education
and income. Other studies found T. gondii seropositivity was associated with decreased
processing speed, regardless of other demographic variables (Massa et al., 2016; Pearce et al.,
2013). Because the studies that found main effects used different measures (Simple Reaction
Time Test versus acoustic startle response), the differences in main effects may be due to
differences in measures.
Language functioning. Compared to other domains, researchers have performed the
least amount of research on the effect of T. gondii seropositivity on language functioning. One
study performed in children by Mendy et al. (2015) found T. gondii seropositive children had
lower reading skills (as measured by the WRAT-R). Additionally, two studies in older adults
used the Word Fluency Test to measure long-term semantic memory (Gajewski et al., 2014,
2016). However, some researchers may also consider the Word Fluency Test to measure verbal
fluency. The studies found those T. gondii seropositive had lower performance on the Word
Fluency Test, which may indicate worse verbal fluency for those T. gondii seropositive. Overall,
however, we can make few conclusions about the potential effect of T. gondii seropositivity on
language functioning due to the scarcity of the research and lack of replication.
Executive functioning. Compared to language functioning, more studies have been
conducted specifically examining executive functioning and T. gondii seropositivity, but there
are still relatively few. Beste, Getzmann, Gajewski, Golka, and Falkenstein (2014) assessed
"goal-directed behavior" in healthy older adults using an auditory distraction task. They found
that T. gondii seropositive older adults had slower reaction times to the tasks and therefore, less
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proficient "goal-directed behavior." Specifically, individuals with higher anti-T. gondii IgG
antibody titers had slower reaction times (Beste et al., 2014).
In a longitudinal study of older adults, researchers examined multiple cognitive domains
over a five-year span (Nimgaonkar et al., 2016). T. gondii seropositive older adults had a faster
decline in executive functioning as well as faster overall changes in cognition as measured by the
MMSE than those seronegative.
Few studies have examined possible associations between T. gondii seropositivity and
executive functioning and more replication studies are needed. The few studies performed have
been done in older adults and have found decreases in executive functioning for those T. gondii
seropositive (Beste et al., 2014; Nimgaonkar et al., 2016). However, in the study by Nimgaonkar
et al. (2016), the authors do not explain clearly what measures of executive functioning were
used, making interpretation and replication by other researchers difficult. Executive functioning
is made of many different components (planning, inhibition, switching, etc.) and Nimgaonkar et
al., (2016) could be measuring any or all of these components while Beste et al. (2014) is likely
measuring inhibition. To properly assess how T. gondii seropositivity may influence executive
functioning, researchers need to examine the different components of executive functioning
rather than just inhibition.
Null or opposite findings. While many studies mentioned above have found an
association between T. gondii seropositivity/infection and effects on cognitive functioning, not
all studies have found an association. For example, one study found motor coordination and
sensory function problems in chronically infected mice (seven weeks post infection) but did not
find any changes in cognitive functioning (as assessed by object recognition and object
placement tasks; Gulinello et al., 2010). Additionally, Dickerson et al. (2014) examined the
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association between cognitive functioning as measured by the Repeatable Battery for the
Assessment of Neuropsychological Status (RBANS) in non-psychiatric controls seropositive for
both acute and latent toxoplasmosis. The researchers found a low total score on the RBANS was
associated with acute toxoplasmosis infection but did not find any associations for those
chronically T. gondii seropositive. However, the RBANS has been shown by Duff, Hobson,
Beglinger, & Bryant (2010) to have lower sensitivity in detecting mild impairments so mild
impairments associated with T. gondii seropositivity may have gone unnoticed in the study.
Many studies find a negative association between T. gondii seropositivity and cognitive
functioning, or a decrease in cognitive functioning associated with seropositivity. However, a
few have found a positive association – T. gondii seropositivity enhancing aspects of cognitive
functioning. One such study examined young adults' executive functioning abilities of switching
and inhibition, and found those T. gondii seropositive performed better at switching tasks (Stock,
von Heinegg, Köhling, & Beste, 2014). However, this positive finding has yet to be replicated
by other studies.
Lastly, many studies have examined T. gondii seropositivity in groups with various
disorders, such as bipolar disorder, HIV, and schizophrenia in comparison to healthy controls.
While Ene et al. (2016) found significant association between T. gondii seropositivity and
decreased overall cognitive performance in those who were HIV positive, they did not find an
association between seropositivity and cognition in healthy controls. In another study, a similar
result was seen for subjects with bipolar disorder (Hamdani et al., 2015). In contrast, two
studies did not find an association between cognitive functioning (such as memory and executive
functioning) and T. gondii seropositivity in people with schizophrenia (Shirts et al., 2009;
Yolken, Torrey, Lieberman, Yang, & Dickerson, 2011). In studies examining bipolar disorder,
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T. gondii may interact with neuroinflammation seen in the disorder, influencing changes in
cognition or vice versa (Hamdani et al., 2015). However, cognitive deficits in schizophrenia
tend to be larger than those common to other psychological disorders so deficits associated with
T. gondii seropositivity may be masked.
Behavioral Changes Associated with T. gondii
Given the widely accepted notion that cognition is associated with behavior, researchers
expect to find behavioral changes due to T. gondii infection in addition to cognitive changes,
and, indeed, researchers have found behavioral changes in rodent models and humans. In studies
examining rats, T. gondii infected rats were observed to be more active and have less fear of
novelty than uninfected rats, as well as to behave in more potentially self-destructive ways such
as demonstrating a lack of fear of and attraction to cat odors, specifically to the odor of cat fur
(Fekadu et al., 2010; Prandovszky et al., 2011; Worth et al., 2014). Specifically, Hutchinson,
Aitken, and Wells (1980) and Hay, Hutchinson, Aitken, and Graham (1983) found infected mice
showed decreased exploration of novel areas. Additionally, Berdoy, Webster, and Macdonald
(1995) found infected rats were more likely to approach a human observer than control rats.
However, in mice, Gulinello et al. (2010) found no difference in the amount of time spent
exploring novel objects between chronically infected and control mice. The most cited and
replicated result in this area seems to an attraction to cat fur odor with seven out of fifteen studies
replicating the result (Worth et al., 2014).
The area of behavior changes most studied in rodents by researchers seems to be motor
deficits associated with T. gondii infection. Chronically infected mice had motor coordination
deficits as tested by a balance beam assay and gait analysis. Specifically, mice had increased
number of slips on the balance beam and increased time to cross the balance beam (Gulinello et
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al., 2010). In addition, other studies found that infected mice fell more often from a rotating
cylinder (Worth et al., 2014). Lastly, approximately equal number of studies have found a
difference in activity level in infected mice (either decreased or increased activity) while other
studies have found no difference in activity (Worth et al., 2014). The differences in results of
motor abilities may be due to decreased levels of dopamine and other catecholamines in infected
mice brains, which has been seen in other studies (Gulinello et al., 2010). Additionally, these
differences in results may be due to differences in mouse strains and/or T. gondii strains used
across studies (Worth et al., 2014).
Along with decreased novelty seeking and motor deficits, some studies have found
increased anxiety in mice infected with T. gondii. Anxiety in rodents in such studies is measured
by decreased time spent on open arms in the elevated plus maze, decreased time spent in social
interaction, and decreased time spent in the middle of an open field (Worth et al., 2014). Some
studies using the open field test found T. gondii infected mice spent less time in the central part
of the open field and one study found a sex difference – infected female mice spent less time in
the middle of the open field but not infected male mice. However, another study found
decreased anxiety in infected mice while another found no difference between infected and
control mice (Worth et al., 2014). The differences seen in anxiety in mice may be due to
differences of how studies measure and define anxiety.
In a human study examining the possible behavior changes due to T. gondii
seropositivity, Flegr (2007) found personality differences based on gender using Cattell’s 16
Personality Factor questionnaire and the Cloninger’s Temperament and Character Inventory. In
T. gondii seropositive males, the researchers found evidence of higher vigilance, suspicion, and
jealousy, but lower superego strength. However, T. gondii seropositive females demonstrated
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higher superego strength, and more factors of warmth, conscientiousness, and moral adherence.
They also found higher levels of apprehension and lower levels of novelty seeking in both T.
gondii seropositive men and women as compared to controls. In addition, Flegr, Kodym, and
Tolarova (2000) found a positive correlation between the duration of T. gondii seropositivity and
personality changes, but only in women. Personality changes associated with T. gondii
seropositivity have rarely been studied in the literature, however, and the results are often
difficult to translate into observable, functional differences between those seropositive and
seronegative.
Some studies have found additional behavior changes in humans including reduced
concentration and a longer reaction time for T. gondii seropositive individuals as well as
increased traffic accidents, especially in those with higher titers of anti-T. gondii IgG antibodies
(Fekadu et al., 2010). Other studies have shown diminished psychomotor performance in T.
gondii seropositive individuals (Dalimi & Abdoli, 2012). Another study did not find an
association between financial risk-taking and T. gondii seropositivity in young adult females,
however (Lanchava, Carlson, Blanka, Flegr, & Nave, 2015). Overall, the studies assessing
reaction time are more well-replicated than those assessing personality factors or financial risktaking. Additionally, a slower reaction time (and subsequently more traffic accidents) are
theoretically related to results showing slower processing speed for those seropositive (Gale et
al., 2014; Massa et al., 2016; Pearce et al., 2013).
From the existing research, the reasons for these behavior modifications in the host of the
parasite are still unclear but one hypothesis is that the parasite may change the host behavior in
order to enhance its transmission rate (Flegr, 2007). Additionally, Worth et al. (2014) suggest
three possibilities for mechanisms on how T. gondii might change host behavior, namely: 1)
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localization of cysts in the brain leading to possible structural damage; 2) variation of
neurotransmitters; and 3) change in immune response of the brain. We will discuss the specifics
of these three possibilities in the next section.
Pathology of T. gondii
In addition to cognitive and behavioral changes associated with T. gondii seropositivity,
studies have found various neurological differences in infected brains, changes that might may
be associated with the development or progression of AD and have been hypothesized to interact
with behavioral and cognitive changes associated with T. gondii seropositivity. These
differences include immune-response changes, specifically inflammation in the CNS, structural
neurological changes due to T. gondii cysts, and dopamine-transmission abnormalities.
Additionally, we will also discuss specific connections to AD pathology in this section.
Inflammation in the CNS. Infection in the brain by T. gondii initiates an immune
response driven by increased CD4 and CD8 T cells. The immune response to T. gondii generates
long-term antigen persistence to the parasite (Brake, 2003). In addition to T cell activation, T.
gondii infection can cause neuroinflammation due to microglia and over-expression of
proinflammatory cytokines. In fact, continuous production of proinflammatory cytokines is
needed for the human body’s resistance to T. gondii (Webster & Mcconkey, 2010). Such
neuroinflammation is present in both T. gondii seropositivity and AD (Freidel, Martin-Solch, &
Schreiter-Gasser, 2002). In a study of chronically infected mice, Hermes et al. (2008) found
increased inflammation in the brain causing neuronal damage including increased CD4 and CD8
T cells and activated microglia, particularly in perivascular areas. Additionally, mice genetically
more resistant to T. gondii infection still showed evidence of increased inflammation in
perivascular areas of the brain but less inflammation as compared to other infected mice (Hermes
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et al., 2008). Specifically in AD, autoaggressive microglia can produce neurotoxins in response
to amyloid exposure (Li et al., 2015). Similarly, in T. gondii infection, pro-inflammatory
cytokines can release nitric oxide which may lead to neuronal and behavioral dysfunction and/or
alter neurotransmitter systems leading to mood and behavior changes (Fekadu et al., 2010).
Of interest is a case of an immunocompromised patient with cerebral toxoplasmosis that
was associated with dementia of the Alzheimer type (Freidel et al., 2002). The patient was
infected with T. gondii one to one and a half years before the presentation of cognitive
impairment. Given these findings, inflammation associated with chronic T. gondii infection
could function as a factor in neurodegenerative diseases in individuals who are genetically
susceptible (Hermes et al., 2008).
Structural neurological changes. T. gondii seropositivity often indicates cysts in the
brains of both humans and rodents. However, there is inconclusive evidence on whether the
number of cysts in a brain (in most studies, rodent brains) plays a role on behavioral or cognitive
changes (Worth et al., 2014). Structurally, there is some evidence that T. gondii infections have
the greatest impacts on the hippocampus and amygdala, areas of importance in AD as well.
Fabiani et al. (2015) reported T. gondii cysts are mainly found in the hippocampus, amygdala,
basal ganglia, cerebellum, cerebral cortex, brain stem, and olfactory bulb. Interestingly,
researchers also found T. gondii cysts in areas high in dopamine including the amygdala and
nucleus accumbens (Fabiani et al., 2015). One study found that cysts in certain combinations of
brain areas were associated with increased risk taking behavior, indicating the parasite may
inhabit particular functional areas of the brain rather than certain areas or structures (Worth et al.,
2014). However, other studies have not found T. gondii cysts to have a preference for particular
areas of the mouse brain (Ihara et al., 2016). The weights of chronically infected mice brains are
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often decreased compared to control brain weights, however. Other studies have observed mild
to moderate ventricular dilation in infected brains of mice (Dalimi & Abdoli, 2012; Worth et al.,
2014).
Dopamine transmission abnormalities. Along with structural brain changes, studies
have found differences in dopamine levels in the brains of mice infected with T. gondii, albeit
with mixed results. Some studies have found increases in dopamine levels (Hodkova, Kodym, &
Flegr, 2007; Prandovszky et al., 2011), whereas others have found decreased levels of dopamine
(Gulinello et al., 2010). In one study, Prandovszky et al. (2011) found increased dopamine in the
T. gondii cyst-containing neural cells and that infected cells release up to 350 percent more
dopamine than uninfected cells. In support of a dopamine imbalance in the brain of infected
mice and humans is the association between schizophrenia and T. gondii seropositivity found by
numerous studies, particularly the imbalance of dopamine between mesolimbic and mesocortical
regions of the brain (Hodkova et al., 2007). Specifically, even in chronic infection, T. gondii can
synthesize L-DOPA and tyrosine, both precursors to dopamine. This production of dopamine
precursors by the parasite has resulted in increased dopamine in rodent brains (Webster et al.,
2013). While lower levels of dopamine have been observed in AD (Dalimi & Abdoli, 2012),
because T. gondii has the ability to make its own dopamine, the parasite may contribute to
dopamine imbalances seen in infection, making the possible variation in dopamine levels found
in T. gondii infection of significance for AD pathology.
AD-associated pathology. ApoE allele E4 is a well-known risk factor for developing
AD. One study examined ApoE genotype and T. gondii seropositivity in persons with and
without dementia and found higher prevalence of dementia in those who were T. gondii
seropositive and who were also non-carriers for the E4 allele. Additionally, when using a
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regression to predict dementia, T. gondii seropositive subjects had a higher risk to develop
dementia, even when researchers included covariates such as age, sex, and ApoE E4 status in the
model (Yahya et al., 2017). Thus, T. gondii seropositivity was a predictor for dementia in this
study while ApoE E4 status was not. This is contradictory to most findings on ApoE and
development of dementia but may provide some insight into the role of T. gondii seropositivity
on development AD.
Another common finding in the pathology of AD is the deposition and lack of clearance
of beta-amyloid plaques. In AD, microglia cells go into a state of senescence and do not remove
beta-amyloid plaques effectively. These microglia also increase neurodegeneration by releasing
proinflammatory cytokines at later stages of AD. In a study investigating the effect of T. gondii
seropositivity on beta-amyloid deposition in mice that rapidly develop beta-amyloid pathology,
the authors found T. gondii infection resulted in reduced number and volume of beta-amyloid
plaques as compared to control mice (Möhle et al., 2016). This change in beta-amyloid plaques
can be viewed as either beneficial or detrimental due to the other immune cells associated with
the removal of beta-amyloid, which cascade of immune cells can worsen neuroinflammation at
certain points in AD. However, the authors speculate that T. gondii infection may act as a strong
stimulus for the immune system, which may ultimately overcome some of the pathology of AD
(Möhle et al., 2016). Similar results were found in two other studies. Specifically, in a line of
AD-model mice (Tg2576, the Swedish APP mutation), one study showed T. gondii infection
reduced cerebral beta-amyloid deposition and increased levels of anti-inflammatory cytokines.
The researchers attributed this to the immunosuppressant effects of T. gondii infection (Carter,
2013). Another mouse study found that T. gondii seropositivity in an AD model of mice
(Tg2576) caused less neuronal death in the hippocampus and fewer beta-amyloid plaques in
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infected mice. AD-model mice that were T. gondii seronegative had reduced cognitive
capacities compared to chronically infected (six months post infection) mice (Jung et al., 2012).
Lastly, evidence from another study suggested opposite reasons for beta-amyloid deposition: a
host may make beta-amyloid plaques to protect against T. gondii because they sequester iron and
iron is needed for replication of tachyzoites (Prandota, 2011). Thus, there seems to be
contradictory evidence on the relationship between T. gondii infection and beta-amyloid
disposition and clearance. Some evidence suggests the parasite is associated with less betaamyloid while others suggest beta-amyloid is a response to infection.
Anosmia is often associated with AD as well as other neurodegenerative disorders and
disorders associated with or potentially started by neuroinflammation. Indeed, olfactory
dysfunction is often one of the first signs of AD. Several studies have found that T. gondii
invades and encysts in olfactory bulb cells in mice (Prandota, 2014). Additionally, one study
found that in male mice, T. gondii infection modulated genes associated with olfactory
functioning. However, overall olfactory tests were normal in infected mice (Prandota, 2014).
On the other hand, one author goes so far as to suggest that the damage caused to the olfactory
bulb by T. gondii may be responsible for the anosmia and olfactory dysfunctions seen in
neurodegenerative diseases such as AD (Prandota, 2014). It is clear that both T. gondii infection
and AD are associated with olfactory dysfunction but the relationship between the two is unclear.
Other results show associations between T. gondii seropositivity and AD that do not
involve the “classic” pathology of AD. Particularly, Prandota et al. (2011) reported changes in
cell cycle in both T. gondii infection and AD as well as disturbances of cerebral metabolic rate
for glucose. Lastly, as mentioned previously, Mahmoudvand, Sheibani, Keshavarz, et al. (2016)
examined the effect of donepezil on memory functioning in T. gondii IgG seropositive mice.
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Importantly, donepezil is a medication often used in the treatment of cognitive problems
associated with AD. Mice treated with donepezil had the short-term memory impairment,
purportedly caused by T. gondii IgG seropositivity, reversed.
Given the evidence of cognitive and behavioral changes, neurological structural
differences and pathology as well as some preliminary evidence of higher T. gondii
seroprevalence in persons with AD, we hypothesize that T. gondii seropositivity may be an
important risk factor in the development of AD. Additionally, given the previous evidence in
both mouse and human studies, we predict that T. gondii seropositivity will negatively affect
cognition in older adults with and without AD and will more negatively impact those with AD
than those without. In the present study, we will assess a larger sample size of participants than
in previous studies performed for associations between T. gondii seropositivity, AD, and
cognitive function in older adults.
Hypotheses
In this study, we used subjects from the Alzheimer’s Disease Research Center (ARDC) at
Washington University (WU) to examine our hypotheses. Specifically, we had a group of
patients with AD and a control group of patients without dementia for comparison. We had data
on T. gondii seropositivity, gender, age, education, socioeconomic status, ethnic background,
neuropsychological data assessing multiple cognitive domains, and other variables that we used
as covariates in our hypotheses and models. In particular, we hypothesized that:
1. T. gondii seropositivity will differ between AD and control groups. That is, T. gondii
seropositivity will be more prevalent in patients with AD. We will evaluate this
hypothesis using t-tests.
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2. T. gondii seropositivity will predict AD diagnosis in matched groups. We will evaluate
this hypothesis using propensity score matching.
3. Memory will be impaired for T. gondii seropositive subjects in both the AD and control
groups. We will assess memory functioning by using scores on Wechsler Memory Scale
Revised (WMS-R) Logical Memory IA subtest, WMS-R Logical Memory IIA subtest,
WMS-R Associate Learning subtest, and Selective Reminding Test (SRT). We will
assess this hypothesis using linear regressions.
4. T. gondii seropositivity will predict worse memory functioning in matched groups, using
the same neuropsychological tests as in the previous hypothesis. We will assess this
hypothesis using propensity score matching.
5. Working memory will be impaired for T. gondii seropositive subjects in both the AD and
control groups. We will assess working memory functioning by using scores on
Wechsler Adult Intelligence Scale (WAIS) Digit Span Forward subtest, WAIS Digit Span
Backward subtest, WMS Mental Control subtest, and WMS Letter Number Sequencing
subtest. We will assess this hypothesis using linear regressions.
6. T. gondii seropositivity will predict worse working memory functioning in matched
groups, using the same neuropsychological tests as in the previous hypothesis. We will
assess this hypothesis using propensity score matching.
7. Processing speed will be impaired for T. gondii seropositive subjects in both the AD and
control groups. We will assess processing speed by using scores on the WAIS Digit
Symbol subtest and Trail Making Test A and B. We will assess this hypothesis using
linear regressions.
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8. T. gondii seropositivity will predict worse processing speed in matched groups, using the
same neuropsychological tests as in the previous hypothesis. We will assess this
hypothesis using propensity score matching.
9. Language functioning will be impaired for T. gondii seropositive subjects in both the AD
and control groups. We will assess language functioning by using scores on the Boston
Naming Test and WAIS Information subtest. We will assess this hypothesis using linear
regressions.
10. T. gondii seropositivity will predict worse language functioning in matched groups, using
the same neuropsychological tests as in the previous hypothesis. We will assess this
hypothesis using propensity score matching.
11. Executive functioning will be impaired for T. gondii seropositive subjects in both the AD
and control groups. We will assess executive functioning by using scores on the WAIS
Block Design subtest, Category Fluency (Animals and Vegetables subtests), and Word
Fluency S & P test. We will assess this hypothesis using linear regressions.
12. T. gondii seropositivity will predict worse executive functioning in matched groups,
using the same neuropsychological tests as in the previous hypothesis. We will assess
this hypothesis using propensity score matching.

Statistical Analyses Theory
In order to test the above hypotheses, we will use two statistical methods. The first is
propensity score matching and the second is linear regression.
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Propensity Score Matching
One difficulty with observational or non-experimental settings is that subjects are seen in
either the treatment condition or the control condition; the experimenters cannot observe the
outcome of the same subject in both conditions. Thus, observational experiments often compare
different subjects in the treatment and control conditions, which means different covariates are
present in each group. This can lead to biases in the data because there can be significant
differences between groups in either measured or unmeasured variables (Andrade, 2017).
Ideally, in our study, we would have liked to observe participants before they became T. gondii
seropositive and then after they became T. gondii seropositive, both under the same conditions,
which would have eliminated any confounding variables that could potentially account for some
of the effect of developing AD due to T. gondii seropositivity or the effect of T. gondii
seropositivity on neuropsychological test scores. However, that was not possible with this
experiment as data were collected by WU before T. gondii seropositivity status was determined.
As such, we determined that using propensity score matching (PSM) would help ameliorate the
difficulties presented with the confounding variables in each treatment group and help come
closer to determining the causal role of T. gondii seropositivity on development of AD and/or
decreased neuropsychological test scores.
PSM is a statistical method used in non-experimental settings to estimate causality.
Specifically, PSM is one technique used to estimate average treatment effects by adjusting for
differences in observable covariates. In PSM, propensity scores are estimated and used to match
similar participants in each treatment group. The propensity score for a subject is the probability
that subject will receive treatment (in this case, be seropositive for T. gondii) given all the control
variables we want to account for in the statistical model (such as age, gender, education, etc.;
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StataCorp, 2013). In our model, we used a logistic regression to make the propensity scores,
using presence or absence of T. gondii seropositivity as the outcome variable and age, education
level, SES status, ethnicity, gender, and the presence or absence of ApoE E4 allele as covariates
for the model. Matches for each subject in the treatment condition (T. gondii seropositive) are
found by determining the closest subject in the control condition (T. gondii seronegative) based
on their propensity scores. Overall, the matched treatment and control groups are similar on
average across the covariates included in the model. The PSM technique estimates the average
treatment effects (ATE) which is the average of the difference between the observed and
potential outcomes of each participant (having AD or not). Additionally, ATE determines if any
differences in outcome between the treatment and matched “control” group are due to the result
of the treatment (e.g. being T. gondii seropositive). Thus, if a large or significant difference is
seen in outcome (having AD) between the treatment group (T. gondii seropositive) and matched
control group (T. gondii seronegative) then we can conclude that treatment (T. gondii
seropositivity) significantly influences the development of AD (StataCorp, 2013). We use the
same technique and theory for the outcome of neuropsychological test scores and how they are
affected by the treatment (T. gondii seropositivity).
Assumptions. PSM has three assumptions associated with its use. The first is the
independent and identically distributed assumption. This assumption specifies that the outcome
and treatment status of each subject need to be separate or unrelated to the outcome and
treatment status of all the other participants included in the study. In other words, in our study,
one participant being T. gondii seropositive cannot influence another participant in the study
being T. gondii seropositive, as well as one participant developing AD cannot influence another
participant developing AD and one person having lower neuropsychological test scores cannot
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influence another person having lower neuropsychological test scores. This assumption excludes
the use of hierarchical or longitudinal data in PSM techniques. In our study, it also makes using
data from immediate family members problematic due to the potential influence of genetics in
developing AD (Alzheimer's Association, 2012) as well as the potential influence of family
members having the same potential factors that would promote becoming seropositive for T.
gondii (such as cat ownership, eating undercooked meat, place of residence, etc.).
Unfortunately, we could not determine if family members of the participants were included in
the study. This data was not available in the dataset received from WU. As such, we
acknowledge that this is a limitation for the study because it can potentially affect causation if
immediate family members are included in the study (StataCorp, 2013).
Another assumption associated with PSM is the conditional independence assumption,
which states that once all the observable variables have been controlled for, the outcome (in this
case, AD or neuropsychological test scores) is independent of assignment to the treatment group
(developing T. gondii seropositivity). In other words, there cannot be any unobserved factors
that influence T. gondii seropositivity, developing AD, and neuropsychological test scores. This
assumption is fairly robust but can be violated if the unobserved variables are on the “causal
pathway” of T. gondii seropositivity leading to the development of AD or influencing
neuropsychological test scores. Known factors influencing T. gondii seropositivity that are not
included in our study include cat ownership and meat-consumption behaviors such as eating
undercooked meat (Alvarado-esquivel et al., 2014; Wei, He, Yang, Lindsay, & Peng, 2016).
However, to our knowledge, these factors do not directly relate to the development of AD or
influence neuropsychological test scores. Country of residence has been associated with T.
gondii seropositivity as well as loosely associated with the development of AD (Brookmeyer,
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Johnson, Ziegler-graham, & Arrighi, 2007; Dubey & Jones, 2008). However, all participants in
the study lived in the United States, eliminating the variation in this factor (StataCorp, 2013).
Lastly, the overlap assumption associated with PSM states that each participant needs to
have a positive probability of receiving treatment, ensuring that each participant could
potentially have all treatment levels. This means in our study, that each participant has to have a
positive probability of being T. gondii seropositive. Given that all participants lived in the
United States, a country known to have an infections with T. gondii, it is likely that each
participant has a positive chance of contracting the disease (StataCorp, 2013).
Proposed models. The models we used with PSM include testing the hypothesis that T.
gondii seropositivity influences the development of AD as well as the hypotheses that T. gondii
seropositivity will negatively affect different domains of cognition including memory, working
memory, language functioning, executive functioning, and processing speed. In each model, we
used the following covariates: age, Hollingshead SES, education level, gender, ethnicity, and
presence or absence of the ApoE E4 allele. We chose these variables as covariates as they all
potentially play a role in influencing the development of AD as well as neuropsychological test
scores (Abate, Marziano, Rungratanawanich, Memo, & Uberti, 2017; Dorey, Chang, Liu, Yang,
& Zhang, 2014; Fiest et al., 2016; S D Gale et al., 2014; Levy et al., 2004). By using PSM in
these proposed models, we will be able to better control for potential cofounding variables as
well as better establish a causal link between T. gondii seropositivity and the development of
AD, if such a link is present. Also, for the neuropsychological test scores outcomes, if a large or
significant difference is seen in outcome (neuropsychological test scores) between the treatment
(T. gondii seropositivity) and matched control group (T. gondii seronegativity) then we can
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conclude that treatment (T. gondii seropositivity) significantly influences the neuropsychological
test scores.
Linear Regression
Bivariate linear regression is a statistical method used to predict an outcome variable (Y)
using a predictor variable (X) with a linear function. Such a method assumes X and Y are
related linearly. In the case of our study, we use linear regression to predict scores on various
neuropsychological tests (Y) based on the presence of T. gondii seropositivity or anti-T. gondii
IgG antibody concentration (X). We determined neuropsychological test scores to be the
outcome variable because it is more probable that T. gondii seropositivity would influence
neuropsychological test scores than the other way around. The linear function of a regression
produces as a result multiple R, which indicates how well the predicted scores for Y match the
actual scores for Y. The larger the R is the closer the actual and predicted Y scores are (Warner,
2013). Additionally, many factors may contribute to the correlation between neuropsychological
test scores and T. gondii seropositivity including gender, age, SES, education, and ApoE status.
We included each of these as a covariate in the regression models.
Assumptions. In a bivariate linear regression, the assumption for the outcome variable is
that it is quantitative, and the predictor variable is assumed to be either quantitative or
dichotomous. Another assumption in bivariate linear regression is that the relationship between
the outcome and predictor variables is linear, as mentioned previously. Linear regressions are
not immune to the effect of extreme outliers, especially when the sample size is small (below a N
of 100, for example). Additionally, large sample sizes are needed in order for the researchers to
find differences between correlations. Lastly, scores on both the outcome and predictor variables
need to have a range applicable to generalization (Warner, 2013).
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Proposed models. The models we used with linear regressions include testing the
hypotheses that T. gondii seropositivity will negatively affect different domains of cognitions
including memory, working memory, language functioning, executive functioning, and
processing speed. In each model, we used the following covariates: gender, age, SES
(Hollingshead Index), level of education, and presence or absence of ApoE E4 allele. Again, we
chose these variables as covariates because they all potentially play a role in influencing the
development of AD (Abate et al., 2017; Dorey et al., 2014; Fiest et al., 2016; S D Gale et al.,
2014; Levy et al., 2004).
Method
Subjects
We received serum samples from 219 subjects from the ADRC at WU in St. Louis
Missouri, Department of Pathology and Immunology. WU deidentified the samples prior to
shipment. We used descriptive statistics to characterize the AD and control groups according to
age, gender, race/ethnicity, socioeconomic status, educational attainment, ApoE E4 status, and
average anti-T. gondii IgG antibody titer concentration. Of the samples, 105 of the subjects were
diagnosed with AD and 114 subjects were age-matched controls without dementia. The
diagnosis of AD was determined by WU using the following: an informant-based semistructured interview assessing six cognitive domains to give the Clinical Dementia Rating (CDR)
score, which interview included 18 relevant scales/questionnaires. The participants in the AD
group had a CDR score of 2 (moderate) or 3 (severe) and all control subjects had a CDR score of
0 (no dementia) with a few exceptions. Namely, 26 participants in the AD group had a CDR
score of 0.5 (questionable) and 25 participants in the same group had a CDR score of 1 (mild)
(Morris, 1993). In the control group, two participants had a CDR score of 0.5, one participant
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had a CDR score of 1, two participants had a CDR score of 2 and three participants had a CDR
score of 3. Because of the potential confounding of controls who have low cognitive functioning
without a diagnosis of AD, we removed from the analysis those controls with a CDR score above
0. Thus, the cognitive status of all subjects was consistent with their diagnosis of either AD or
control.
Neuropsychological data. We received neuropsychological data from most participants,
which included the following measures: Boston Naming Test, Category Fluency (Animal and
Vegetable), Word Fluency, Trail Making Test A and B, and Wechsler Memory Scale-Revised
(WMS-R; Digit Span Forward and Backward, Logical Memory Story A: Immediate and
Delayed; Associate Learning; Mental Control), Free and Cued Selective Reminding Test,
Wechsler Adult Intelligence Scale (WAIS; Block Design, Information), Wechsler Adult
Intelligence Scale-Revised (WAIS-R; Digit Symbol), and Wechsler Adult Intelligence Scale-III
(WAIS-III; Letter-Number Sequencing). We grouped the neuropsychological test data based on
which cognitive domain each test assessed. We used WMS-R Logical Memory IA, WMS-R
Logical Memory IIA, WMS-R Associate Learning, and Free and Cued Selective Reminding Test
as measures of memory. We used WMS-R Digit Span Forward, WMS-R Digit Span Backward,
WMS-R Mental Control, and WAIS-III Letter-Number Sequencing as measures of working
memory. We used WAIS-R Digit Symbol and Trail Making Tests A and B as measures of
processing speed. We used the Boston Naming Test and WAIS Information as measures of
language functioning. Lastly, we used WAIS Block Design, Category Fluency (Animal and
Vegetable), and Word Fluency as measures of executive functioning (Nuechterlein et al., 2004;
Sheline et al., 2006).
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According to the information provided by WU, WU gave the neuropsychological tests
used in these analyses in the following manner for each test:
Boston Naming Test: The examiners began at item one and presented all 30 oddnumbered items (pictures of objects) in order, to the subject. They allowed 20 seconds for each
response. If the subject gave a response that indicated a misperception of the picture, the
examiner would give the assigned stimulus cue. Again, the subject was allowed 20 seconds to
respond. If the subject gave an incorrect response following the stimulus cue then the examiner
gave the assigned phonemic cue. The total score of the test is the number of items named
correctly, including those named correctly following stimulus cues (Fisher et al., 1999;
Goodglass & Kaplan, 1983b; Kaplan, Goodglass, & Weintraub, 1983; Mack, Freed, Williams, &
Henderson, 1992).
Category Fluency – Animals and Vegetables: For Animal Category Fluency, the
examiner asked the subject to name as many different animals as they can for 60 seconds.
Similarly, for Vegetable Category Fluency, the examiner asked the subject to name as many
different vegetables as they can for a minute. The total score for both Animal and Vegetable
Category Fluency was the total number of correct responses in a minute for each (Goodglass &
Kaplan, 1983a).
Word Fluency: This test consisted of two parts. First, the examiner asked the subject to
name as many words as they can that begin with the letter P. Second, the examiner asked the
subject to name as many words as they can that begin with the letter S (Thurstone & Thurstone,
1949). We used the combined score of both P and S subtests in the analyses.
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Trailmaking A and B: For Trailmaking A, the examiner asked the subject to connect 25
numbered circles in sequential order. The score is the time in seconds it took the subject to
connect the circles. The test was stopped at 150 seconds if the subject had not finished
(Armitage, 1945). For Trailmaking B, the examiner asked the subject to connect numbered
circles (numbered from 1-13) and lettered circles (from A-L) in alternating sequential order
within the 180 second limit. The total score is the time in seconds it took the subject to connect
the circles (Armitage, 1945).
WMS-R Digit Span Forward: The examiner gave this test according to the WMS-R
manual. Briefly, the examiner gave a series of numbers (of increasing length) which the subject
had to repeat in the same order. The score for the test was the longest sequence of numbers the
subject repeated correctly (Wechsler, 1987).
WMS-R Digit Span Backward: The examiner gave this test according to the WMS-R
manual. The examiner gave a sequence of numbers (of increasing length) which the subject had
to repeat in reverse order. The score for the test was the longest sequence of numbers the subject
repeated in reverse order correctly (Wechsler, 1987).
WMS-R Logical Memory Story A, Immediate and Delayed: The examiner gave this test
according to the WMS-R manual except that the examiner only administered Story A. The
examiner read Story A to the subject and asked the subject to tell back as much of the story as
he/she could remember immediately after hearing the story, the Immediate part of the test. The
examiner then asked the subject to recall as much of the story as he/she could remember at least
30 minutes after originally hearing it, the Delayed part of the test. The score for each part of the
test was the number of parts of the story correctly recalled, according to the WMS-R manual
(Wechsler, 1987).
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WMS-R Associate Learning: The examiner presented the subject with eight word pairs,
four “easy” pairs that are easily associated and four “hard” pairs that are not readily associated.
The examiner read the word pair list three times, with a memory trial after each reading.
Subjects who had not learned the pairs by the third trial had up to three more trials to learn the
pairs. The word pairs were randomized in each of the learning trials. About thirty minutes later,
the examiner gave a single recall trial. The total score is based on the correctly recalled word
pairs on the first three trials (Wechsler & Stone, 1973).
Free and Cued Selective Reminding Test: The examiner presented the subject with
sixteen items to be learned, four at a time on a card. The examiner asked the subject to give the
name of a pictured item (e.g. grapes) when presented with a category cue (e.g., fruit). To
confirm the encoding of the items, the examiner asked the subject to recall the items on each card
(four at a time) immediately after reviewing the items on the card. This also provided retrieval
practice before the test phase. The subject performed three recall trials with each trial preceded
by 20 seconds of interference by counting backwards from 97 by threes. The examiner allowed
the subject up to ninety seconds to recall items for each recall trial. Additionally, the examiner
gave the category cue for each item not initially recalled. If the subject did not recall the item
within ten seconds after the category cue, the examiner told the participant what it was. The
score used in these analyses is the total number of items recalled in the three recall trials, for both
freely recalled items and items cued with a category cue (Grober, Buschke, Crystal, Bang, &
Dresner, 1988).
WAIS Block Design: The examiner asked the subject to replicate models or pictures of
two-color designs with blocks. The examiner scored and administered the test according to the
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WAIS manual. The score for the test was the total score of points earned for each attempt at
replication (Wechsler, 1955).
WAIS Information: The subject answered a series of questions about factual information.
The examiner scored and administered the test according to the WAIS manual. The score for the
test was the total score of questions answered correctly (Wechsler, 1955).
WAIS-R Digit Symbol: The examiner gave the subject a piece of paper with a code of a
symbol for each number (1-9) at the top of the page. The examiner instructed the subject to use
the code to fill in empty boxes below symbols. The examiner asked the subject to fill in as many
correct numbers as possible, in order, without skipping any, in 90 seconds. One point was given
for each correct number entered within the time limit (Wechsler, 1981).
WMS-III Letter-Number Sequencing: The examiner read a combination of numbers of
letters and asked the subject to repeat them, saying the numbers first in ascending order and then
the letters in alphabetical order. The examiner administered and scored the test according to the
WMS-III manual (Wechsler, 1997). The score for the test was the number of points given for
each correct sequence of letters and numbers.
WMS Mental Control: This test consisted of a combined score from three subtests of the
WMS Mental Control test. First, the examiner asked the subject to count backwards from 20 in
30 seconds and which the examiner scored according to the WMS manual. Second, the
examiner asked subject to repeat the alphabet in 30 seconds. Lastly, the examiner asked the
subject to count from one to 40 by threes in 45 seconds. (Wechsler & Stone, 1973). The
examiner only scored items completed within time limits. The examiner scored the items on a
three-point scale: no errors equaled two points; one error equaled one point; and no credit if there
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were two or more errors. The score we used in the analyses was the summary score of the three
subtests.
We compared the average scores on the neuropsychological measures using t-tests in a
few different comparisons, namely, comparing neuropsychological scores between those
seropositive and seronegative for latent Toxoplasmosis (in both the AD and control groups),
between males and females (in both the AD and control groups), and between the AD and
control groups.
The BYU IRB office determined IRB approval for this study was not needed due to the
lack of direct contact with participants and our use of previously-collected, deidentified data.
Procedure
ELISA assays. We assessed serum samples with quantitative immunoenzymatic
determination of T. gondii IgG-class antibodies using ELISA analysis with a commercially
available kit (GenWay, BioTech). We performed all assays according to the protocol provided
by the manufacturer. We diluted all serum samples 1:100 with IgG Sample Diluent by
dispensing 10 uL of the sample and 1 mL IgG Sample Diluent and then thoroughly mixing with
a vortex. We dispensed 100 uL of each Standard (A, B, C, and D) into the respective wells,
leaving the first well (A1) empty as a blank. We covered the wells with foil supplied in the kit
and incubated the plate for one hour at 37 degrees Celsius. After completion of the incubation,
we aspirated the contents of the wells and washed each well three times with 300 uL of washing
solution. After washing, we dispensed 100 uL of the Toxoplasma anti-IgG Conjugate solution
into all wells except for the blank well. We then covered the plates covered with foil and
incubated them for thirty minutes at room temperature (20 to 25 degrees Celsius). We washed
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the wells again as previously stated. We then dispensed 100 uL of the TMB Substrate Solution
into each well after which, we covered the wells with foil and incubated them at room
temperature (20 to 25 degrees Celsius) in the dark. After incubation, we dispensed 100 uL of the
Stop Solution into all wells in the same order and at the same rate as the TMB Substrate
Solution. We measured the absorbance of each well at 450mm using an ELISA Microwell Plate
Reader directly after we added the Stop Solution. We used the empty well in position A1 as the
blank for absorbency measurements. We assayed all samples in duplicate and we calculated the
mean absorbency value from the two sample absorbency values. We created a calibration curve
by plotting the absorbance values of the Standards included in the assay (Standards A, B, C, D)
against their corresponding concentrations (0, 50, 100 and 200 mL, respectively) using a linear
regression function in Excel (Microsoft). We determined the anti-T. gondii IgG antibody
concentration of each sample by using the calibration curve. In accordance with the protocol
provided by the manufacturer, we considered samples with an IgG anti-T. gondii titer greater
than 35 IU/mL as positive. We considered samples below 30 IU/mL non-reactive. We
reassayed samples in the equivocal range (30-35 IU/ mL), a total of two samples overall.
Additionally, we diluted fivefold and tenfold and reassayed samples with absorbencies outside
the standard curve computed for each assay. For the samples we reassayed, we adjusted the
absorbencies according to dilution factor. In addition to the positive standard provided in the
assay, we included a sample shown to be positive with another assay (Abcam) when assaying
each plate as an additional positive control. Lastly, we reassayed three to four samples from
each plate a second time as a quality control to ensure reproducibility. In order to reduce the
influence of pipetting error on the results, we calibrated all pipettes before we began the assays
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and we used the same pipettes for all runs. Additionally, the person conducting the assays was
blind to gender and ADRC diagnosis.
The presence of IgG anti-T. gondii antibodies in the serum in the absence of IgM
antibodies is indicative of a past infection with T. gondii, whereas the presence of IgM antibodies
is considered indicative of an acute or reactivated T. gondii infection. In an effort to distinguish
between acute and a latent infection with T. gondii, we assayed all samples seropositive or
borderline seropositive for IgG antibodies to determine the titer of IgM anti-T. gondii antibodies
using a commercially available IgM-specific ELISA kit (GenWay, BioTech) following the
protocol provided by the manufacturer. We diluted all serum samples 1:40 with Sample Diluent
by combining 5 uL of serum sample with 200 uL of Sample Diluent. We diluted the Negative
Control, Positive Control, and Calibrator (provided in the kit) 1:40 in the same manner. We then
thoroughly mixed the diluted serum samples, Negative Control, Positive Control, and Calibrator
with a vortex. We dispensed 100 uL of the diluted Negative Control, Positive Control,
Calibrator, and serum samples into their respective wells. In the first well (A1), we dispensed
100 uL of Sample Diluent as a blank. We covered the wells with foil supplied in the kit and
incubated the plate for thirty minutes at 37 degrees Celsius. After completion of the incubation,
we aspirated the contents of the wells and washed each well five times with 300 uL of washing
solution. After washing, we dispensed 100 uL of the Enzyme Conjugate solution (provided by
the kit) into all wells. We then gently mixed the wells for ten seconds. Afterwards, we covered
the plates with foil and incubated for thirty minutes at 37 degrees Celsius. We again washed the
wells as previously stated. We then dispensed 100 uL of the TMB Reagent solution into each
well and again mixed gently for 10 seconds. We covered the wells with foil and incubated the
plate at 37 degrees Celsius for 15 minutes. After incubation, we dispensed 100 uL of the Stop
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Solution into all wells in the same order and at the same rate as the TMB Substrate Solution. We
then gently mixed the wells for 30 seconds. We measured the absorbance of each well at 450mm
by an ELISA Microwell Plate Reader directly after we added the Stop Solution. We used the
well in position A1 filled with Sample Diluent as the blank for absorbency measurements. We
assayed all samples in duplicate and calculated the mean absorbency value from the two sample
absorbency values. To determine if samples were positive for anti-T. gondii IgM antibodies, we
calculated the mean cut-off calibrator value, positive control, and negative control. We
determined the Toxoplasma IgM Index by dividing the mean values of each sample by the
calibrator mean value. According to the protocol, we considered a Toxoplasma IgM Index value
greater than one as positive for IgM antibodies to T. gondii, an Index between 0.91 and 0.99 as
equivocal, and an Index value below 0.90 as negative. In order to determine the assay was
performed correctly, we measured the optical density (OD) for the first well (reagent blank) and
was below 0.250, the recommended cut-off by the manufacturer for the reagent blank.
Additionally, we measured the OD value for the Calibrator and it was below 0.250, again the
recommended cut-off value provided by the manufacturer. We performed another quality
control check by determining the Toxoplasma IgM Index for the Positive and Negative Controls.
The Toxoplasma IgM Index for both the Positive and Negative Controls were within the ranges
provided by the kit which is indicative of correct implication of the assay. Only two serum
samples were positive for anti-T. gondii IgM antibodies, which we removed from the analyses.
We performed these analyses in the laboratories of Dr. Brent Nielsen and Dr. Eric Wilson at
BYU.
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Statistical Analysis
Data cleaning. In order to determine the accuracy of the data being used in the study, we
carefully examined the data using STATA software version 13.1 (StataCorp). First, we recoded
the anti-T. gondii IgG antibody titer concentration variable to become the presence or absence of
T. gondii seropositivity variable by designating all values of concentration below 29.999 to be
“0” in the new variable and all values above 30 to be “1” in the new variable. Because the antiT. gondii IgG antibody titer concentration variable was not normally distributed despite fencing
the variable for outliers, we transformed the variable by taking the natural log of the variable.
This made the distribution of the antibody-titer variable considerably more normal. Also, we
recoded the “dx” variables (cognitive disorder diagnosis by WU) into a dichotomous variable for
AD. If the “dx” variable was “DAT” (“dementia of the Alzheimer’s type”), “DAT Language
dysf with,” “DAT w/ProAph w/dement at onset,” “DAT w/depression, contribut”, “DAT
w/depression, not contribut”, “DAT w/oth (list B) not contrib”, or “DAT/other prior to DAT” we
coded the new AD variable as “1”. Otherwise, we coded the AD variable as “0”. We excluded
any participants with diagnoses from WU of “DLBD, primary” (“dementia, Lewy-body
dementia”), “Incipient demt PTP”, “Unc: ques. Impairment”, “uncertain dementia”, and “DAT
cannot be primary.” As mentioned previously, we dropped from the analysis any samples that
were not diagnosed with AD but had a CDR rating of 0.5 or greater. We did this to prevent those
with some form of cognitive decline (that perhaps had not been diagnosed) from being included
in the controls. We excluded a total of eight subjects. We also excluded subjects that only had
data for T. gondii seropositivity but no other data (clinical, neuropsychological, etc.). We
excluded a total of eight subjects because they only had data from the T. gondii seropositivity
analysis. We decided to keep all races/ethnicities in the analyses (rather than excluding
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minorities and only using the majority represented race/ethnicity) because of the ability to match
based on race/ethnicity in propensity score matching analyses. Originally, we coded level of
education as the number of years of education the participant had achieved. To simplify
analyses, we recoded the level of education variable as those with eleven or less years of
education as “1”; participants with 12 years of education (a high school education) as “2”; and
those participants with 13 or more years of education as “3”. In this reclassification, the higher
the category classification, the more education the participant had attained. Lastly, we did not
fence or modify neuropsychological test variables because the test variables were already
bounded by the test themselves. Each test has a limit of how many points are possible as well as
the lowest score possible.
Due to missing data in the dataset provided by WU, we considered using multiple
imputations to help reduce bias that can occur due to missing data and listwise deletion. Most of
our covariates (age, ApoE E4 allele, SES, education level, gender, ethnicity) and predictor
variables had very little to no missing data with the highest percent of missing data being 2.7.
However, many of our dependent variables (neuropsychological test scores) had missing data
that ranged from 10.5 percent to 73.1 percent. Due to the large amount of missing data on some
dependent variables, Young and Johnson (2017) suggest the use of the multiple imputation, then
deletion (MID) method. In this method, the researcher imputes all variables (including the
dependent variables) and then deletes those cases that have imputed data on the dependent
variables before performing analyses. Because the majority of missing data are in dependent
variables for our dataset, our using the MID method would negate the benefits of multiple
imputations because the large majority of the imputed data would be deleted (all except seven
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data points). Because of these limitations and due to the majority of the missing data being in
the dependent variables, we decided not to use multiple imputations in our analyses.
Propensity score matching. To perform propensity score matching analyses, we used
the “psmatch” command in STATA. This command estimates treatment effects from
observational data by imputing the missing potential outcome for each participant (either the
treatment outcome or no treatment outcome, which is the outcome for T. gondii seropositivity or
T. gondii seronegativity in this study) using the average of similar participants that have the other
treatment level. This similarity of participants is determined by making propensity scores, which
scores are the probabilities of a participant being assigned to a particular treatment group with a
specific set of covariates (StataCorp, 2013). In the case of our study, the “treatment” is a person
being T. gondii seropositive and the non-treatment group are those T. gondii seronegative. The
outcome used to determine the propensity scores is diagnosis of AD. The covariates we used in
the model to make the propensity scores included age, SES Hollingshead Index, education level,
gender, ethnicity, and presence or absence of ApoE E4 allele. We performed a logistic
regression (due to the binary nature of the outcome AD) with T. gondii seropositivity and the
above-mentioned covariates to determine the propensity scores, using the following model:
logistic toxo age seshollingsheadindex educ ethn gender apoecoded
predict ps
replace ps = 1/ps if toxo==1
replace ps = 1/(1-ps) if toxo==0
To test the first hypothesis, that T. gondii seropositivity will predict diagnosis of AD, we
used the following model:
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teffects psmatch (ad) (toxo age seshollingsheadindex educ ethn gender apoecoded, logit)
In addition to determining the effect of T. gondii seropositivity on diagnosis of AD, we
also were interested in determining the effect of T. gondii seropositivity on cognitive domains
using propensity score matching. As such, we made the following models for each
neuropsychological domain/test as the outcome:
Memory tests:
WMS-R Logical Memory IA (Immediate):
teffects psmatch (logimemwmslogicalmemoryiai) (toxo age seshollingsheadindex educ
ethn gender apoecoded, logit)
WMS-R Logical Memory IIA (Delayed):
teffects psmatch (memunitswmslogicalmemoryiia) (toxo age seshollingsheadindex educ
ethn gender apoecoded, logit)
WMS Associate Learning:
teffects psmatch (asscmemwmsassociatelearning) (toxo age seshollingsheadindex educ
ethn gender apoecoded, logit)
SRT Total Score:
teffects psmatch (srttotal) (toxo age seshollingsheadindex educ ethn gender apoecoded,
logit)
Working memory:
WMS-R Digit Span Forward:
teffects psmatch (digtordigitspanforward) (toxo age seshollingsheadindex educ ethn
gender apoecoded, logit)
WMS-R Digit Span Backward:
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teffects psmatch (digbackdigitspanbackward) (toxo age seshollingsheadindex educ ethn
gender apoecoded, logit)
WMS Mental Control:
teffects psmatch (mentalctrl) (toxo age seshollingsheadindex educ ethn gender
apoecoded, logit)
WAIS-III Letter Number Sequencing:
teffects psmatch (lnsequence) (toxo age seshollingsheadindex educ ethn gender
apoecoded, logit)
Processing Speed:
Trailmaking A:
teffects psmatch (tmatrailmakinga) (toxo age seshollingsheadindex educ ethn gender
apoecoded, logit)
Trailmaking B:
teffects psmatch (tmbtrailmakingb) (toxo age seshollingsheadindex educ ethn gender
apoecoded, logit)
WAIS-R Digit Symbol:
teffects psmatch (digsymwaisdigitsymbol) (toxo age seshollingsheadindex educ ethn
gender apoecoded, logit)
Language Functioning:
Boston Naming Test:
teffects psmatch (bntbostonnamingtesttotalcor) (toxo age seshollingsheadindex educ ethn
gender apoecoded, logit)
WAIS Information:
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teffects psmatch (psy019waisinformation) (toxo age seshollingsheadindex educ ethn
gender apoecoded, logit)
Executive Functioning:
WAIS Block Design:
teffects psmatch (psy021waisblockdesign) (toxo age seshollingsheadindex educ ethn
gender apoecoded, logit)
Category Fluency – Animals:
teffects psmatch (animalscategoryfluency) (toxo age seshollingsheadindex educ ethn
gender apoecoded, logit)
Category Fluency – Vegetables:
teffects psmatch (vegcategoryfluency) (toxo age seshollingsheadindex educ ethn gender
apoecoded, logit)
Word Fluency S & P:
teffects psmatch (wordfluency) (toxo age seshollingsheadindex educ ethn gender
apoecoded, logit)
Lastly, we also employed propensity score matching to determine the effect of T. gondii
seropositivity on cognitive domains within each group, the AD group and the control group. We
separated the analyses because of the great differences in neuropsychological test scores between
the two groups. The models for the two groups were the same as those above, just with notation
to only analyze one group at a time.
Linear regressions. In addition to performing propensity score matching analyses, we
also performed linear regressions to predict scores for each neuropsychological test using two
models. The first model included the dichotomous measure of T. gondii seropositivity or
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seronegativity, and the second included the log-transformed, continuous measure of anti-T.
gondii IgG antibody titers. Both models included gender, socioeconomic status, education level
(categorized), age, race/ethnicity, and ApoE status (presence or absence of E4 allele) as control
variables as well as an interaction term to help determine the interaction of group (AD and
control) with the main predictor, either T. gondii seropositivity/seronegativity or anti-T. gondii
IgG antibody titer concentration. We included ApoE status as a control variable due to its
known association with both Alzheimer’s disease and cognitive decline (Abate et al., 2017;
Dorey et al., 2014; Fiest et al., 2016). Additionally, Levy et al. (2004) Levy et al. found those
carrying an E4 allele of ApoE had lower scores on WMS-R Logical Memory IIA. Given these
findings, we wanted to control the potential effect ApoE status may have on memory function
and thus included it in our analyses. In each model, the differences in sample size are due to
missing data on the dependent variables.
In order to perform the linear regression analyses we used the “reg” command in STATA
(StataCorp). Below are the models used for each neuropsychological test domain with models
for both T. gondii seropositivity status (coded “toxo”) and anti-T. gondii IgG antibody titer
concentration (coded “concln”) as predictors with an interaction for group (“ad” coded as “1” for
the AD group and “0” for the control group). We coded the control variables as follows: gender
as “gender” with male being the reference variable; age as “age” as a continuous variable; SES
(from the Hollingshead Index) as “ses” and as a categorical variable; level of education as “edu”
and as a categorical variable; presence or absence of ApoE E4 allele as “apoecoded” and as a
dichotomous variable with no E4 allele as the reference variable; and ethnicity as “ethn” as a
dichotomous variable (because only two ethnicities were represented in the dataset, African
American and White) with White as the reference variable. The neuropsychological variables
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were coded as follows: WMS-R Logical Memory IA as “logimemwmslogicalmemoryiai”;
WMS-R Logical Memory IIA as “memunitswmslogicalmemoryiia”; WMS Associate Learning
as “asscmemwmsassociatelearning”; Free and Cued Selective Reminding Test as “srttotal”;
WMS-R Digit Span Forward as “digfordigitspanforward”; WMS-R Digit Span Backward as
“digbackdigitspanbackward”; WMS Mental Control as “mentalctrl”; WAIS-III Letter Number
Sequencing as “lnsequence”; WAIS-R Digit Symbol as “digsymwaisdigitsymbol”; Trailmaking
Test A as “tmatrailmakinga”; Trailmaking Test B as “tmbtrailmakingb”; WAIS Information as
“psy019waisinformation”; Boston Naming Test as “bntboston”; WAIS Block Design as
“psy021waisblockdesign”; Category Fluency – Animals as “animalscategoryfluency”; Category
Fluency – Vegetables as “vegcategoryfluency”; and Word Fluency as “wordfluency”.
Memory:
reg logimemwmslogicalmemoryiai ad##c.concln i.gender c.age i.ses i.edu i.apoecoded
i.ethn
reg logimemwmslogicalmemoryiai ad##toxo i.gender c.age i.ses i.edu i.apoecoded i.ethn
reg memunitswmslogicalmemoryiia ad##c.concln i.gender c.age i.ses i.edu i.apoecoded
i.ethn
reg memunitswmslogicalmemoryiia ad##toxo i.gender c.age i.ses i.edu i.apoecoded i.ethn
reg asscmemwmsassociatelearning ad##c.concln i.gender c.age i.ses i.edu i.apoecoded
i.ethn
reg asscmemwmsassociatelearning ad##toxo i.gender c.age i.ses i.edu i.apoecoded i.ethn
reg srttotal ad##c.concln i.gender c.age i.ses i.edu i.apoecoded i.ethn
reg srttotal ad##toxo i.gender c.age i.ses i.edu i.apoecoded i.ethn
Working Memory:
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reg digfordigitspanforward ad##c.concln i.gender c.age i.ses i.edu i.ethn i.apoecoded
reg digfordigitspanforward ad##toxo i.gender c.age i.ses i.edu i.ethn i.apoecoded
reg digbackdigitspanbackward ad##c.concln i.gender c.age i.ses i.edu i.ethn i.apoecoded
reg digbackdigitspanbackward ad##toxo i.gender c.age i.ses i.edu i.ethn i.apoecoded
reg mentalctrl ad##c.concln i.gender c.age i.ses i.edu i.ethn i.apoecoded
reg mentalctrl ad##toxo i.gender c.age i.ses i.edu i.ethn i.apoecoded
reg lnsequence ad##c.concln i.gender c.age i.ses i.edu i.ethn i.apoecoded
reg lnsequence ad##toxo i.gender c.age i.ses i.edu i.ethn i.apoecoded
Processing Speed:
reg digsymwaisdigitsymbol ad##c.concln i.gender c.age i.ses i.edu i.ethn i.apoecoded
reg digsymwaisdigitsymbol ad##toxo i.gender c.age i.ses i.edu i.ethn i.apoecoded
reg tmatrailmakinga ad##c.concln i.gender c.age i.ses i.edu i.ethn i.apoecoded
reg tmatrailmakinga ad##toxo i.gender c.age i.ses i.edu i.ethn i.apoecoded
reg tmbtrailmakingb ad##c.concln i.gender c.age i.ses i.edu i.ethn i.apoecoded
reg tmbtrailmakingb ad##toxo i.gender c.age i.ses i.edu i.ethn i.apoecoded
reg digsymwaisdigitsymbol ad##c.concln i.gender c.age i.ses i.edu i.ethn i.apoecoded
reg digsymwaisdigitsymbol ad##toxo i.gender c.age i.ses i.edu i.ethn i.apoecoded
Language functioning:
reg psy019waisinformation ad##c.concln i.gender c.age i.ses i.edu i.ethn i.apoecoded
reg psy019waisinformation ad##toxo i.gender c.age i.ses i.edu i.ethn i.apoecoded
reg bntboston ad##c.concln i.gender c.age i.ses i.edu i.ethn i.apoecoded
reg bntboston ad##toxo i.gender c.age i.ses i.edu i.ethn i.apoecoded
Executive Functioning:
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reg psy021waisblockdesign ad##c.concln i.gender c.age i.ses i.edu i.ethn i.apoecoded
reg psy021waisblockdesign ad##toxo i.gender c.age i.ses i.edu i.ethn i.apoecoded
reg animalscategoryfluency ad##c.concln i.gender c.age i.ses i.edu i.ethn i.apoecoded
reg animalscategoryfluency ad##toxo i.gender c.age i.ses i.edu i.ethn i.apoecoded
reg vegcategoryfluency ad##c.concln i.gender c.age i.ses i.edu i.ethn i.apoecoded
reg vegcategoryfluency ad##toxo i.gender c.age i.ses i.edu i.ethn i.apoecoded
reg wordfluency ad##c.concln i.gender c.age i.ses i.edu i.ethn i.apoecoded
reg wordfluency ad##toxo i.gender c.age i.ses i.edu i.ethn i.apoecoded
Because of the potential for alpha inflation due to the high amount of linear regressions
we performed, we performed the Benjamini-Hochberg procedure. We used the BenjaminiHochberg procedure because it gives much greater power than the Bonferroni technique. We
implemented the procedure using the information given in Thissen, Steinberg, and Kuang
(2002).
In addition, we also performed power analyses for the linear regressions in the study. We
used the “powerreg” command in STATA and estimated the power of each regression rather than
estimating the sample size needed to attain a certain power level. Below is an example of the
code we used to do a power analysis for WMS-R Logical Memory as an outcome and T. gondii
seropositivity status as the predictor.
reg logimemwmslogicalmemoryiai ad##toxo i.gender c.age i.ses i.edu i.ethn i.apoecoded
local r2f = e(r2)
reg logimemwmslogicalmemoryiai i.ad i.gender c.age i.ses i.edu i.ethn i.apoecoded
local r2r = e(r2)
powerreg, r2f(`r2f') r2r(`r2r') nvar(11) ntest(1) n(117)
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Results

Sample Characteristics
We used descriptive statistics to characterize the AD and control groups according to age,
gender, race/ethnicity, socioeconomic status, educational attainment, ApoE E4 status, and
average anti-T. gondii IgG antibody titer concentration. Fifty-four percent of the participants
diagnosed with AD were female and 52 percent of control participants were female. The average
age for those in the AD group was 80.4 years (standard deviation of 7.2 years) and 79.1 years
(standard deviation of 7.0 years) in the control group. The percent of participants with greater
than a high school education in the AD group was 53 and 72 percent for participants in the
control group. We used the Hollingshead two-factor index of social position to estimate
socioeconomic status, with a “1” on the scale representing higher socioeconomic status. The
range of possible values on the scale are from 1 to 5 (Hollingshead & Redlich, 1958). The
average Hollingshead SES index value for the AD group was 3.4 (standard deviation of 1.2) and
an average index of 3.8 (standard deviation of 1.0) for the control group. Sixty-one percent of
the AD group had at least one E4 allele for the ApoE gene while only 28 percent of the control
group had one E4 allele. The percent T. gondii seropositive in the AD group was 59 compared to
68 percent T. gondii seropositive in the control group. The average anti-T. gondii antibody
concentration for the control group 140.9 IU/mL with a range of -7.2 to 1351.8 IU/mL. The
average anti-T. gondii antibody concentration for the AD group was 108.1 IU/mL with a range of
0.3 to 940.8 IU/mL. Additionally, we examined the frequency of a history of hypertension,
diabetes, heart disease, thyroid disease, alcohol abuse, tobacco use and hypercholesterolemia in
each group, and found no significant difference between them. Only a history of stroke was
significantly different between groups, being more prevalent in the AD group than in the control
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group (p=0.03; 4.7% versus 0.9%, respectively). We present demographic information, anti-T.
gondii antibody concentrations and t-test results for differences between the two groups on each
demographic variable in Table 1.
T-Test Results
Between the two groups there are significant differences between percent Caucasian (p
=0.006), level of education (p =0.002), SES (p = 0.01), and presence of ApoE E4 allele (p =
Table 1
Characteristics of AD and Control Groups.
Characteristics

AD

Controls

t

p value

[95% CI]

105

114

.

.

.

80.40, 7.18,
[61.57-97.80]

79.06, 7.02,
[62.06-98.28]

-1.39

0.17

[78.7680.65]

Women (%)

54.29

51.75

-0.37

0.71

[1.46-1.60]

Ethnic Background (% Caucasian)

100.00

92.98

2.80

0.01**

[0.01-0.06]

Education (% more than High School)

53.33

71.93

3.07

0.002*
*

[2.43-2.62]

SES (Hollingshead Index), mean, SD

3.42, 1.20

3.81, 0.99

2.61

0.01**

[3.47-3.77]

59.05

67.54

-1.30

0.19

[-0.21-0.04]

140.94,
260.74, [-7.15- -1.05
1351.84]

0.30

[-94.4228.80]

0.001*
**

[0.37-0.51]

Sample size
Age (years), mean, SD, [range]

T. gondii seropositive (%)
Anti-T. gondii IgG antibody
concentration IU/mL, mean, SD,
[range]
ApoE status (% with E4 allele)

108.13,
199.97,
[0.29-940.81]
60.95

28.07

-5.11

Note. * p value = or < 0.05 ** p value < 0.01; *** p value < 0.001.

0.001) with the control group having more African Americans, higher average level of education,
lower average level of SES, and lower incidence of ApoE E4 allele than the AD group (Table 1).
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The two groups did not significantly differ on the other demographic measures. When we
compared performance on neuropsychological measures between the control and AD groups, all
neuropsychological tests scores were significantly different between the two groups (p = 0.001)
with participants in the control group performing better than those in the AD group, which is
what we expected (Table 2). When we compared scores on neuropsychological measures
between males and females only two tests showed significant differences, namely, the Boston
Naming Test (p = 0.03) and WAIS Information (p = 0.01). On both measures, men performed
significantly better than females (Table 3). Lastly, when we compared neuropsychological test
scores of those T. gondii seropositive and seronegative (in both the control and AD groups), four
tests showed significant differences, specifically Selective Reminding Test (p = 0.05), Digit
Symbol (p = 0.04), Block Design (p =0.03), and Category Fluency Animals (p =0.01). Those T.
gondii seronegative performed significantly better all on the measures mentioned (Table 4).
Propensity Score Matching Results
After we matched the treatment (T. gondii seropositivity) and matched control group (T.
gondii seronegativity) on the covariates, there was not a significant difference in outcome
(having AD) between the groups. Thus, T. gondii seropositivity does not seem to significantly
influence the development of AD in this sample (Table 5).
In addition to testing the influence of T. gondii seropositivity on development of AD, we
also tested the effect of T. gondii seropositivity on neuropsychological test scores using
propensity score matching. For most neuropsychological test scores, we found no significant
difference in outcome between the treatment (T. gondii seropositivity) and matched control
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Table 2
Neuropsychological Test Scores for AD and Control Groups.
Neuropsychological Test

AD

Control

t

p value

[95% CI]

WMS-R Logical Memory IA, mean, SD

5.64, 4.36

14.01, 4.26

9.03

0.001***

[11.01-13.04]

WMS-R Logical Memory IIA, mean, SD

3.68, 4.36

12.97, 4.66

9.35

0.001***

[9.66-11.87]

WMS-R Associate Learning, mean, SD

7.41, 3.73

14.30, 3.63

12.99

0.001***

[10.53-11.96]

Free and Cued Selective Reminding Test,
mean, SD

13.83, 8.41

29.15, 6.15

10.77

0.001***

[23.98-27.27]

WMS-R Digit Span Forward, mean, SD

5.77, 1.19

6.62, 1.08

5.21

0.001***

[6.07-6.41]

WMS-R Digit Span Backward, mean, SD

3.63, 1.35

4.77, 1.25

6.12

0.001***

[4.07-4.47]

WMS-R Mental Control, mean, SD

5.13, 2.93

7.47, 1.68

7.03

0.001***

[6.06-6.79]

WAIS-III Letter-Number Sequencing,
mean, SD

5.67, 4.69

9.06, 2.22

3.47

0.001***

[7.77-9.31]

23.98, 15.81

46.10, 9.88

11.73

0.001***

[33.90-38.76]

81.81, 51.38

36.96,
18.10

-8.43

0.001***

[50.50-62.67]

156.57,
36.36

95.91,
36.70

-10.97

0.001***

[114.25128.13]

Boston Naming Test, mean, SD

40.28, 13.40

54.92, 6.20

10.06

0.001***

[11.77-17.51]

WAIS Information, mean, SD

12.80, 6.50

21.68, 4.56

11.19

0.001***

[16.77-18.76]

WAIS Block Design, mean, SD

16.93, 11.91

30.08, 8.40

8.85

0.001***

[22.65-26.11]

Category Fluency – Animal, mean, SD

8.96, 4.92

20.12, 5.94

13.90

0.001***

[14.21-16.43]

Category Fluency – Vegetables, mean, SD

7.34, 3.72

14.11, 3.87

8.26

0.001***

[11.57-13.33]

18.04, 10.12

30.16, 9.88

8.36

0.001***

[23.23-26.53]

WAIS-R Digit Symbol, mean, SD
Trails A, mean, SD
Trails B, mean, SD

Word Fluency, mean, SD

Note. * p value = or < 0.05; ** p value < 0.01; *** p value < 0.001.
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Table 3
Neuropsychological Test Scores for Males and Females in AD and Control Groups.
Neuropsychological Test

Males

Females

t

p value

[95% CI]

WMS-R Logical Memory IA, mean, SD

11.8, 5.32

12.22, 5.80

-0.41

0.68

[11.01-1.62]

WMS-R Logical Memory IIA, mean, SD

10.51, 5.72

10.98, 6.37

-0.42

0.67

[9.66-11.87]

WMS-R Associate Learning, mean, SD

10.65, 4.99

11.80, 5.01

-1.60

0.11

[-2.57-0.27]

Free and Cued Selective Reminding Test,
mean, SD

25.07, 9.02

26.14, 9.62

-0.64

0.52

[23.98-27.27]

WMS-R Digit Span Forward, mean, SD

6.19, 1.20

6.29, 1.20

-0.55

0.58

[-0.44-0.24]

WMS-R Digit Span Backward, mean, SD

4.15, 1.26

4.38, 1.54

-1.13

0.26

[-0.63-0.17]

WMS-R Mental Control, mean, SD

6.72, 2.50

6.16, 2.65

1.54

0.13

[6.06-6.79]

WAIS-III Letter-Number Sequencing,
mean, SD

9.26, 2.72

7.75, 3.04

2.01

0.05*

[0.01-3.01]

WAIS-R Digit Symbol, mean, SD

36.21, 16.17

36.44, 17.62

-0.09

0.92

[33.90-38.76]

Trails A, mean, SD

56.76, 44.13

56.41, 41.63

0.05

0.96

[50.50-62.67]

Trails B, mean, SD

117.90,
46.48

124.20, 47.91

-0.89

0.37

[114.25128.13]

Boston Naming Test, mean, SD

50.40, 11.99

46.47, 12.58

2.22

0.03*

[46.59-50.11]

WAIS Information, mean, SD

19.09, 6.61

16.53, 7.25

2.56

0.01**

[16.77-18.76]

WAIS Block Design, mean, SD

26.08, 11.86

22.74, 11.92

1.92

0.06

[22.65-26.11]

Category Fluency – Animal, mean, SD

16.28, 8.25

14.39, 7.28

1.70

0.09

[14.21-16.43]

Category Fluency – Vegetables, mean,
SD

12.00, 4.92

12.83, 4.72

-0.93

0.35

[11.57-13.33]

Word Fluency, mean, SD

25.52, 11.98

24.29, 11.35

0.73

0.47

[23.23-26.53]

Note. * p value = or < 0.05; ** p value < 0.01; *** p value < 0.001.
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Table 4
Neuropsychological Test Scores for Those T. Gondii Seropositive and Seronegative in AD and
Control Groups.
Neuropsychological Test

Seropositive

Seronegative

t

p value

[95% CI]

WMS-R Logical Memory IA, mean, SD

11.73, 5.61

12.18, 5.57

0.42

0.68

[10.92-13.45]

WMS-R Logical Memory IIA, mean, SD

10.61, 6.10

10.84, 6.07

0.20

0.84

[9.66-11.87]

WMS-R Associate Learning, mean, SD

10.61, 4.89

11.63, 5.08

1.38

0.17

[10.53-11.96]

Free and Cued Selective Reminding Test,
mean, SD

23.43, 9.75

26.80, 8.92

1.96

0.05*

[23.98-27.27]

WMS-R Digit Span Forward, mean, SD

6.32, 1.20

6.19, 1.21

-0.76

0.45

[6.07-6.41]

WMS-R Digit Span Backward, mean, SD

4.08, 1.38

4.38, 1.42

1.44

0.15

[4.07-4.47]

WMS-R Mental Control, mean, SD

6.16, 2.92

6.59, 2.36

1.12

0.26

[6.06-6.79]

WAIS-III Letter-Number Sequencing,
mean, SD

9.00, 3.17

8.33, 2.78

-0.82

0.42

[7.77-9.31]

WAIS-R Digit Symbol, mean, SD

32.91, 16.44

38.27, 16.90

2.11

0.04*

[33.90-10.37]

Trails A, mean, SD

62.89, 46.40

52.88, 40.21

-1.57

0.12

[50.56-62.67]

Trails B, mean, SD

129.25, 45.04

116.74, 47.97

-1.71

0.09

[114.25128.13]

Boston Naming Test, mean, SD

46.16, 13.64

49.67, 11.50

1.92

0.06

[46.59-50.11]

WAIS Information, mean, SD

17.08, 7.31

18.18, 6.88

1.06

0.29

[16.77-18.76]

WAIS Block Design, mean, SD

21.96, 12.06

25.83, 11.74

2.16

0.03*

[22.65-26.11]

Category Fluency – Animals, mean, SD

13.55, 7.66

16.40, 7.73

2.49

0.01**

[14.21-16.43]

Category Fluency – Vegetables, mean,
SD

11.76, 4.10

12.82, 5.13

1.14

0.26

[11.57-13.33]

Word Fluency, mean, SD

22.97, 11.81

26.04, 11.43

1.79

0.07

[23.23-26.53]

Note. * p value = or < 0.05; ** p value < 0.01; *** p value < 0.001.
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Table 5
Propensity Score Matching Results for AD Outcomes: Presence of T. Gondii Seropositivity
Predicting Outcome of Group Membership.
Outcome
AD

Coefficient
-0.05

Std. Error
0.08

z
-0.64

p value
0.52

[95% CI]
[-0.19-0.10]

Note. The following covariates were included as part of the matching criteria in the analysis: age,
SES status, education level, ethnicity, gender, and presence or absence of ApoE E4.

group (T. gondii seronegativity). However, for the processing speed test of WAIS-R Digit
Symbol, we found a significant difference (p = 0.052) between the treatment and matched
control group, indicating T. gondii seropositivity may play a role in the performance of this
neuropsychological test (Table 6).
As mentioned previously, in addition to performing propensity score matching with
neuropsychological tests for the whole group, we also employed the procedure for the AD and
control groups separated. For most neuropsychological test scores, we again found no
significant difference in outcome between the treatment (T. gondii seropositivity) and matched
groups (T. gondii seronegativity) for those in the AD group. However, for the processing speed
test of Trailmaking B and executive functioning test of WAIS Block Design, we found a
significant difference (p = 0.011 and p=0.026, respectively) between the treatment and matched
groups, indicating T. gondii seropositivity may play a role in the performance of these
neuropsychological tests in the AD group (Table 7). When assessing the control group only, no
significant differences were seen between treatment and matched groups (Table 8).
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Table 6
Propensity Score Matching Results for Neuropsychological Test Outcomes: Presence of T.
Gondii Seropositivity Predicting Outcome of Each Test.
Neuropsychological test outcome

Coefficient

Std. Error

z

p value

[95% CI]

Logical Memory IA

-0.76

1.33

-0.57

0.57

[-3.38-1.86]

Logical Memory IIA

-0.21

1.45

-0.14

0.89

[-3.05-2.64]

Associate Memory

-0.53

0.83

-0.64

0.52

[-2.15-1.10]

SRT Total

0.08

0.61

0.13

0.90

[-1.12-1.28]

Digit Span – Forward

0.19

0.21

0.88

0.38

[-0.23-0.60]

Digit Span – Backward

-0.22

0.21

-1.06

0.29

[-0.63-0.19]

Mental Control

-0.28

0.44

-0.64

0.53

[-1.13-0.58]

Letter Number Sequencing

0.90

0.51

1.75

0.08

[-0.11-1.90]

Trails A

3.81

8.70

0.44

0.66

[-13.24-20.85]

Trails B

4.12

9.21

0.45

0.66

[-13.94-22.18]

Digit Symbol

-5.26

2.70

-19.5

0.05

[-10.55-0.04]

Boston Naming Test

-1.08

2.04

-0.53

0.60

[-5.07-2.91]

WAIS Information

0.01

1.12

0.00

0.99

[-2.19-2.20]

WAIS Block Design

-2.16

1.76

-1.22

0.22

[-5.61-1.29]

Category Fluency – Animals

-0.33

1.19

-0.28

0.78

[-2.68-2.00]

Category Fluency – Vegetables

-0.24

0.85

-0.28

0.78

[-1.91-1.43]

Word Fluency S & P

-1.93

1.94

-1.00

0.32

[-5.73-1.87]

Note. The following covariates were included as part of the matching criteria in the analysis: age,
SES status, education level, ethnicity, gender, and presence or absence of ApoE E4.
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Table 7
Propensity Score Matching Results for Neuropsychological Test Outcomes for AD Group Only:
Presence of T. Gondii Seropositivity Predicting Outcome of Each Test.
Neuropsychological test outcome

Coefficient

Std. Error

z

p value

[95% CI]

Logical Memory IA

-0.89

0.99

-0.90

0.37

[-2.84, 1.06]

Logical Memory IIA

-0.11

1.13

-0.10

0.92

[-2.32, 2.10]

Associate Memory

-0.69

0.72

-0.96

0.34

[-2.11, 0.72]

SRT Total

0.59

0.97

0.60

0.55

[-1.32, 2.49]

Digit Span – Forward

0.23

0.31

0.74

0.46

[-0.38, 0.85]

Digit Span – Backward

-0.35

0.37

-0.94

0.35

[-1.08, 0.38]

Mental Control

-0.72

0.68

-1.06

0.29

[-2.06, 0.61]

Trails A

7.45

11.49

0.65

0.52

[-15.07, 29.98]

Trails B

20.47

8.05

2.54

0.01

[4.69, 36.24]

Digit Symbol

1.49

3.22

0.46

0.64

[-4.81, 7.80]

Boston Naming Test

-0.84

3.11

-0.27

0.79

[-6.94, 5.26]

WAIS Information

0.05

1.48

0.03

0.98

[-2.86, 2.95]

WAIS Block Design

-4.69

2.11

-2.23

0.03

[-8.82, -0.56]

Category Fluency – Animals

-1.53

0.99

-1.55

0.12

[-3.47, 0.41]

Category Fluency – Vegetables

1.59

1.84

0.86

0.39

[-2.02, 5.19]

Word Fluency S & P

-0.80

1.98

-0.40

0.69

[-4.67, 3.08]

Note. The following covariates were included as part of the matching criteria in the analysis: age,
SES status, education level, ethnicity, gender, and presence or absence of ApoE E4.
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Table 8
Propensity Score Matching Results for Neuropsychological Test Outcomes for Control Group
Only: Presence of T. Gondii Seropositivity Predicting Outcome of Each Test.
Neuropsychological test outcome

Coefficient

Std. Error

z

p value

[95% CI]

Logical Memory IA

-0.02

0.97

-0.02

0.98

[-1.92, 1.87]

Logical Memory IIA

0.46

1.09

0.42

0.67

[-1.68, 2.60]

Associate Memory

0.41

0.74

0.55

0.58

[-1.05, 1.86]

SRT Total

0.02

0.12

0.17

0.87

[-0.22, 0.26]

Digit Span – Forward

0.40

0.22

1.82

0.07

[-0.03, 0.83]

Digit Span – Backward

-0.22

0.24

-0.95

0.34

[-0.68, 0.24]

Mental Control

-0.31

0.38

-0.82

0.41

[-1.06, 0.44]

Letter Number Sequencing

0.88

0.48

1.83

0.07

[-0.06, 1.82]

Trails A

0.79

2.20

0.36

0.72

[-3.51, 5.10]

Trails B

2.31

9.89

0.23

0.82

[-17.09, 21.70]

Digit Symbol

-2.03

2.07

-0.98

0.33

[-6.08, 2.03]

Boston Naming Test

-0.37

1.21

-0.31

0.76

[-2.73, 2.00]

WAIS Information

-0.11

0.86

-0.13

0.90

[-1.79, 1.57]

WAIS Block Design

-3.50

1.89

-1.84

0.07

[-7.21, 0.22]

Category Fluency – Animals

-0.04

1.65

-0.02

0.98

[-3.28, 3.20]

Category Fluency – Vegetables

-0.30

0.97

-0.30

0.76

[-2.20, 1.61]

Word Fluency S & P

-0.32

1.77

-0.18

0.85

[-3.78, 3.14]

Note. The following covariates were included as part of the matching criteria in the analysis: age,
SES status, education level, ethnicity, gender, and presence or absence of ApoE E4.
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Additionally, we performed post-estimation commands for all significant results found
using propensity score matching. The post-estimation command of “overlap” allowed us to
examine the overlap of the propensity scores made for each group (seropositive and seronegative
groups). For each significant result, the overlap analyses showed the propensity scores from
each group overlapped each other and neither group had many scores around zero or one
probability. Given these results, we can determine the overlap assumption of propensity score
matching has not been violated in our analyses (StataCorp, 2013).
Linear Regression Results
Memory neuropsychological measures. In the linear regression analyses, anti-T. gondii
antibody titer was not significantly associated with any of the memory measures in the control or
AD groups in the model including control variables. Additionally, we found T. gondii
seropositivity was not significantly associated with any of the memory measures in the control or
AD groups (Table 9).
Working memory neuropsychological measures. In the linear regression analyses, we
found anti-T. gondii antibody titer was positively associated with performance on the WMS-R
Digit Span Forward test (p= 0.052) and WMS Letter-Number Sequencing test (p= 0.050; Table
10). Additionally, we found T. gondii seropositivity was positively associated with WMS LetterNumber Sequencing test (p= 0.046; Table 10). We found no other associations between working
memory measures and seropositivity.
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Table 9
Main Effects Models of Anti-T. Gondii Antibody Titer or Presence of T. Gondii Seropositivity
and Each Memory Test Score: Unstandardized Coefficients (Standard Errors) From Linear
Regression.
Logical Memory IA

Logical Memory
IIA

Associate Memory

Selective
Reminding Test

b

SE

b

SE

b

SE

b

SE

Antibody titer

0.308

0.301

0.387

0.322

0.147

0.234

-0.099

0.323

Seropositive & AD
(Group interaction)

-0.880

0.592

-1.190

0.633

-0.255

0.334

0.567

0.583

Female

0.588

0.862

0.939

0.923

1.463**

0.551

-1.228

0.886

Age

-0.006

0.060

0.012

0.064

-0.024

0.040

-0.039

0.061

2

5.028

4.557

4.011

4.877

-2.247

2.156

-0.338

4.874

3

4.968

4.477

2.828

4.791

-1.140

2.177

0.254

4.843

4

4.637

4.462

2.524

4.775

-2.354

2.198

0.454

4.818

5

5.171

4.574

2.206

4.895

-1.540

2.257

0.503

4.913

High School

1.605

1.916

0.813

2.051

-0.815

1.007

-3.998*

1.995

More than High
School

2.664

2.047

3.484

2.191

0.109

1.096

-5.674**

2.120

African American

-0.750

1.621

-1.950

1.735

-3.478**

1.339

0.174

1.752

ApoE (presence of E4)

-0.843

0.935

-0.558

1.001

-0.814

0.593

-3.004**

0.966

Constant

6.158

7.191

5.020

7.696

17.270

4.176

57.330

7.298

SES (Hollingshead
Index)

Education

R2

0.476

0.491

0.535

0.464

n

113

113

187

122

Power

0.09

0.19

0.74

0.75
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Table 9 Continued
Logical Memory IA

Logical Memory
IIA

Associate
Memory

Selective
Reminding Test

b

SE

b

SE

b

SE

b

SE

Presence of T. gondii
seropositivity

-0.155

0.984

0.131

1.056

-0.119

0.770

0.034

1.055

Seropositive & AD
(Group interaction)

-0.782

1.948

-0.971

2.090

-0.083

1.107

2.480

2.043

Female

0.486

0.839

0.791

0.900

1.286*

0.540

-1.215

0.869

Age

0.002

0.060

0.017

0.064

-0.014

0.039

-0.046

0.061

2

5.210

4.548

4.313

4.879

-2.152

2.163

-1.099

4.885

3

5.194

4.472

3.261

4.798

-0.866

2.187

-0.683

4.859

4

4.814

4.452

2.916

4.776

-1.824

2.199

-0.123

4.837

5

5.521

4.566

2.796

4.898

-1.077

2.265

-0.190

4.940

High School

1.564

1.836

0.861

1.970

-0.792

0.998

-4.039*

1.907

More than High
School

2.713

1.930

3.451

2.070

-0.119

1.054

-5.483**

1.988

African American

-0.578

1.621

-1.723

7.839

-3.350**

1.346

0.247

1.757

ApoE (presence of E4)

-1.273

0.894

-0.930

0.959

-0.888

0.583

-3.430**

0.942

Constant

6.520

7.275

5.693

7.806

16.914

4.136

58.247

7.400

SES (Hollingshead
Index)

Education

R2

0.473

0.487

0.518

0.443

n

117

117

193

125

Power

0.09

0.08

0.06

0.32

Note. * p value = or < 0.05; ** p value < 0.01; *** p value < 0.001.
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Table 10
Main Effects Models of Anti-T. Gondii Antibody Titer or Presence of T. Gondii Seropositivity
and Each Working Memory Test Score: Unstandardized Coefficients (Standard Errors) from
Linear Regression.
Digit Span Forward

Digit Span
Backward

WMS Mental
Control

WMS LetterNumber Sequencing

b

SE

b

SE

b

SE

b

SE

Antibody titer

0.145*

0.074

-0.004

0.083

0.122

0.144

0.485*

0.213

Seropositivity & AD
(Group interaction)

-0.088

0.106

-0.020

0.119

-0.221

0.205

-0.253

0.644

Female

0.211

0.173

0.391*

0.194

-0.132

0.336

-0.994

0.640

Age

-0.001

0.013

0.004

0.014

-0.033

0.025

-0.182**

0.049

2

-0.819

0.681

0.296

0.766

0.698

1.325

.

.

3

-0.190

0.689

0.471

0.775

2.224

1.338

4.051**

1.221

4

-0.117

0.694

0.879

0.781

1.906

1.351

3.891**

1.183

5

-0.059

0.713

0.927

0.802

2.423

1.387

4.799**

1.307

High School

0.077

0.331

0.459

0.372

-0.242

0.619

-5.650**

1.829

More than High
School

0.008

0.357

0.500

0.402

0.291

0.672

-6.293**

1.960

African American

-0.103

0.423

-0.422

0.476

-1.592

0.823

-1.023

0.970

ApoE (presence of E4)

0.152

0.188

0.242

0.212

0.295

0.363

-2.075**

0.754

Constant

6.189

1.340

3.045

1.507

7.625

2.553

24.816

4.348

SES (Hollingshead
Index)

Education

R2

0.184

0.244

0.346

0.600

n

188

188

189

56

Power

0.51

0.43

0.58

0.68
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Table 10 Continued
Digit Span
Forward

Digit Span
Backward

WMS Mental
Control

WMS LetterNumber Sequencing

b

SE

b

SE

b

SE

b

SE

Presence of T. gondii
seropositivity

0.352

0.240

-0.128

0.272

0.343

0.466

1.393*

0.680

Seropositivity & AD
(Group interaction)

-0.109

0.346

0.028

0.392

-0.867

0.670

-1.573

1.937

Female

0.174

0.168

0.353

0.190

-0.213

0.327

-1.041

0.640

Age

0.000

0.013

0.008

0.014

-0.024

0.024

-0.193**

0.049

2

-0.766

0.677

0.285

0.767

0.781

1.318

.

.

3

-0.148

0.686

0.565

0.777

2.356

1.333

3.711**

1.262

4

-0.063

0.688

1.007

0.779

2.149

1.339

3.248**

1.193

5

-0.043

0.709

1.067

0.802

2.560

1.379

4.112**

1.350

High School

0.085

0.325

0.298

0.368

-0.336

0.608

-5.822**

1.870

More than High
School

-0.002

0.341

0.298

0.386

0.114

0.641

-5.961**

2.029

African American

-0.046

0.421

-0.396

0.477

-1.517

0.820

-0.917

0.978

ApoE (presence of E4)

0.130

0.183

0.190

0.208

0.320

0.353

-2.273**

0.727

Constant

6.467

1.317

2.801

1.491

7.222

2.507

27.337

4.382

SES (Hollingshead
Index)

Education

R2

0.181

0.233

0.336

0.594

n

194

194

195

58

Power

0.44

0.09

0.27

0.63

Note. * p value = or < 0.05; ** p value < 0.01; *** p value < 0.001.
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Processing speed neuropsychological measures. In the linear regression analyses, we
found anti-T. gondii antibody titer was not significantly associated with any of the processing
speed measures in the models including control variables. Additionally, we found T. gondii
seropositivity was not significantly associated with any of the processing speed measures (Table
11).
Language functioning neuropsychological measures. In the linear regression analyses,
we found anti-T. gondii antibody titer was not significantly associated with any of the language
functioning measures in the models including control variables. Additionally, we found T.
gondii seropositivity was not significantly associated with any of the language functioning
measures (Table 12).
Executive functioning neuropsychological measures. In the linear regression analyses,
we found anti-T. gondii antibody titer was not significantly associated with any of the executive
functioning measures the models including control variables. Additionally, we found T. gondii
seropositivity was not significantly associated with any of the executive functioning measures
(Table 13).
We found other expected associations between many neuropsychological measures and
covariates such as AD, gender, level of education, presence of ApoE E4 allele, ethnicity, and
SES for both T. gondii seropositivity and anti-T. gondii antibody titer models. We expected
these associations and they were not the main purpose of the analyses.
Benjamini-Hochberg results. Due to the potential for alpha inflation from the many
linear regressions we performed, we performed the Benjamini-Hochberg procedure to counteract
potential alpha inflation. Based on the Benjamini-Hochberg critical values produced, the two
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Table 11
Main Effects Models of Anti-T. Gondii Antibody Titer or Presence of T. Gondii Seropositivity
and Each Processing Speed Test Score: Unstandardized Coefficients (Standard Errors) from
Linear Regression.
WAIS Digit Symbol

Trails A

Trails B

b

SE

b

SE

b

SE

Antibody titer

-0.564

0.780

-0.415

2.309

-0.598

2.195

Seropositivity & AD (Group
interaction)

0.716

1.121

3.016

3.322

3.268

3.201

Female

1.945

1.957

-1.205

5.423

2.130

5.303

-0.338*

0.138

0.644

0.410

1.539**

0.412

2

4.627

7.157

2.608

21.234

-28.234

20.202

3

13.511

7.244

-23.064

21.531

-41.688*

20.497

4

10.848

7.294

-16.421

21.641

-31.014

20.603

5

14.010

7.508

-20.231

22.226

-36.480

21.254

High School

0.525

3.392

13.966

10.464

7.346

10.578

More than High School

1.654

3.724

15.163

11.258

0.981

11.988

-11.403**

4.445

35.365**

13.182

41.424**

12.486

ApoE (presence of E4)

-0.634

2.004

-3.131

5.958

4.954

5.765

Constant

61.891

14.201

-10.958

42.274

3.204

41.789

Age
SES (Hollingshead Index)

Education

African American

R2

0.540

0.367

0.538

n

181

185

173

Power

0.61

0.51

0.82

T. GONDII AND COGNITION

70

Table 11 Continued
WAIS Digit Symbol
b

Trails A

SE

Trails B

b

SE

b

SE

Presence of T. gondii
seropositivity

-2.622

2.602

-0.404

7.707

-2.027

7.321

Seropositivity & AD (Group
interaction)

0.960

3.760

6.968

11.146

16.422

11.061

Female

1.286

1.821

-2.975

5.373

4.020

5.225

Age

-0.321*

0.135

0.806*

0.407

1.513**

0.407

2

4.854

7.182

2.967

21.507

-28.046

20.391

3

13.591

7.279

-20.769

21.831

-42.370*

20.711

4

11.939

7.299

-13.281

21.859

-34.788

20.714

5

14.562

7.534

-18.745

22.510

-37.482

21.424

High School

1.379

3.359

7.591

10.455

8.102

10.490

More than High School

1.707

3.570

7.583

10.913

3.278

11.473

African American

-11.449**

4.469

35.622**

13.376

40.718**

12.639

ApoE (presence of E4)

-0.271

1.967

-3.085

5.898

5.336

5.682

Constant

58.862

14.038

-19.448

42.321

2.803

41.638

R2

0.531

0.356

0.525

n

187

191

179

Power

0.23

0.14

0.45

SES (Hollingshead Index)

Education

Note. * p value = or < 0.05; ** p value < 0.01; *** p value < 0.001.
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Table 12
Main Effects Models of Anti-T. Gondii Antibody Titer or Presence of T. Gondii Seropositivity
and Each Language Functioning Test Score: Unstandardized Coefficients (Standard Errors)
from Linear Regression.
WAIS Information

Boston Naming Test

b

SE

b

SE

Antibody titer

0.301

0.329

0.047

0.617

Seropositivity & AD (Group interaction)

-0.247

0.470

-0.422

0.879

Female

-1.655*

0.773

-2.737

1.451

Age

-0.034

0.056

-0.193

0.107

2

-0.185

3.034

-1.950

5.679

3

1.867

3.064

3.403

5.740

4

2.401

3.094

3.662

5.787

5

4.284

3.175

5.039

5.946

High School

1.392

1.417

-0.782

2.653

More than High School

2.274

1.542

-1.125

2.889

African American

-4.223*

1.884

-12.532**

3.529

ApoE (presence of E4)

-0.189

0.834

0.303

1.578

Constant

20.112

5.877

69.956

11.108

SES (Hollingshead Index)

Education

R2

0.534

0.469

n

188

187

Power

0.45

0.30
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Table 12 Continued
WAIS Information

Boston Naming Test

b

SE

b

SE

Presence of T. gondii seropositivity

-0.254

1.072

-0.635

2.035

Group interaction

0.218

1.545

-1.721

2.909

Female

-1.748*

0.754

-3.043*

1.416

Age

-0.004

0.055

-0.164

0.105

2

0.211

3.028

-2.041

5.669

3

2.223

3.062

3.688

5.738

4

2.760

3.079

4.022

5.762

5

4.717

3.169

5.270

5.939

High School

1.425

1.397

-1.941

2.615

More than High School

2.195

1.475

-2.077

2.762

African American

-4.107*

1.884

-12.398**

3.530

ApoE (presence of E4)

-0.153

0.815

-0.170

1.541

Constant

18.597

5.789

69.053

10.922

SES (Hollingshead Index)

Education

R2

0.525

0.468

n

194

193

Power

0.06

0.23

Note. * p value = or < 0.05; ** p value < 0.01; *** p value < 0.001.
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Table 13
Main Effects Models of Anti-T. Gondii Antibody Titer or Presence of T. Gondii Seropositivity
and Each Executive Functioning Test Score: Unstandardized Coefficients (Standard Errors)
from Linear Regression.
WAIS Block Design

Category
Fluency –
Animals

Category
Fluency –
Vegetables

Word Fluency S &
P

b

SE

b

SE

b

SE

b

SE

Antibody titer

0.137

0.598

-0091

0.341

-0.219

0.273

-0.507

0.622

Seropositivity & AD
(Group interaction)

-1.018

0.865

-0.415

0.491

0.446

0.531

0.197

0.896

Female

-2.249

1.425

-1.652*

0.800

0.636

0.786

0.301

1.468

Age

-0.097

0.108

-0.126*

0.059

-0.082

0.053

-0.028

0.107

2

1.363

5.497

-0.157

3.136

7.094

4.106

-1.658

5.730

3

5.992

5.558

0.212

3.177

7.959*

4.064

0.047

5.790

4

3.483

5.594

1.811

3.203

7.713

4.040

-0.101

5.863

5

7.073

5.749

1.715

3.286

7.917

4.142

1.723

6.007

High School

-4.597

2.643

0.036

1.526

-1.235

1.599

2.420

2.683

More than High School

-1.143

2.853

0.077

1.649

-1.425

1.740

5.021

2.920

-12.180**

3.407

-2.814

1.947

-2.158

1.470

-10.539**

3.559

0.119

1.552

-0.633

0.869

-0.569

0.832

0.483

1.584

36.615

10.999

30.182

6.101

14.905

6.269

30.030

11.15
0

SES (Hollingshead Index)

Education

African American
ApoE (presence of E4)
Constant
R2

0.478

0.570

0.402

0.369

n

180

186

113

186

Power

0.97

0.22

0.74

0.22
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Table 13 Continued
WAIS Block
Design

Category
Fluency –
Animals

Category
Fluency –
Vegetables

Word Fluency S &
P

b

SE

b

SE

b

SE

b

SE

Presence of T. gondii
seropositivity

-1.108

2.007

-0.702

1.099

-1.240

0.878

-1.366

2.013

Seropositivity & AD
(Group interaction)

-3.529

2.940

-0.513

1.602

2.560

1.708

-0.397

2.924

Female

-2.684

1.415

-1.736*

0.774

0.844

0.747

0.487

1.422

Age

-0.074

0.107

-0.134*

0.057

-0.092

0.052

-0.030

0.104

2

1.835

5.583

-0.366

3.100

-7.241

4.013

-1.999

5.686

3

6.300

5.654

0.175

3.145

7.950*

3.973

-0.257

5.752

4

4.591

5.668

1.639

3.157

7.410

3.942

-0.354

5.798

5

7.644

5.840

1.567

3.248

7.750

4.045

1.640

5.959

High School

-4.032

2.651

0.038

1.491

-0.717

1.508

2.267

2.631

More than High School

-0.825

2.777

0.161

1.561

-0.671

1.614

5.267

2.775

12.071**

3.468

-2.849

1.928

-2.383

1.438

-10.677**

3.537

ApoE (presence of E4)

0.070

1.543

-0.741

0.840

-0.525

0.780

0.123

1.539

Constant

34.852

11.022

30.908

5.974

14.689

6.211

29.003

10.916

SES (Hollingshead Index)

Education

African American

R2

0.452

0.577

0.452

0.368

n

186

192

117

192

Power

0.64

0.24

0.43

0.20

Note. * p value = or < 0.05; ** p value < 0.01; *** p value < 0.001.
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regressions that had significant results (for the WMS-R Digit Span Forward and WMS LetterNumber Sequencing tests) are no longer significant and were likely spurious results due to the
large number of regressions performed (Table 14).
Power analysis results. Taking 0.80 as the cutoff for detecting an effect when there is
an effect to be detected (Cohen, 1988), only two regressions were at or above 0.80 (association
between anti-T. gondii antibody titer and Trailmaking B; association between anti-T. gondii
antibody titer and WAIS Block Design). We determined all other regressions had power
estimates much lower than 0.80 except for three: association between anti-T. gondii antibody
titer WMS Associate Memory (power estimate of 0.74), Free and Cued Selective Reminding
Test (power estimate of 0.75), and Category Fluency Vegetables (power estimate 0.74; Tables 913).
Discussion
In contrast to the study by Kusbeci et al. (2011), we did not find a significantly higher
prevalence of T. gondii seropositivity in those with AD compared to control subjects without
dementia. Moreover, we did not find significant differences in the average natural logtransformed anti-T. gondii IgG antibody titers between the two groups. Additionally, T. gondii
seropositivity did not predict diagnosis of AD. However, other studies examined the association
between T. gondii seropositivity and AD and also did not find an association (Mahami-oskouei et
al., 2016; Rashno et al., 2016). Our findings are similar to the latter studies, although our study
had a larger sample size than any of the previous studies (219 compared to 71, 174, and 150,
respectively). Interestingly, some mouse studies have supported the idea that T. gondii
seropositivity actually protects from AD infection, an idea similar to our results that T. gondii
seropositivity did not predict AD diagnosis. Specifically, one study found that T. gondii
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Table 14
Results of Benjamini-Hochberg Procedure for Each Linear Regression.
Benjamini-Hochberg
Critical Value

p value less than
critical value

Logical Memory IA – Antibody titer

0.006

No

Logical Memory IA – Presence of seropositivity

0.021

No

Logical Memory IIA – Antibody titer

0.004

No

Logical Memory IIA – Presence of seropositivity

0.022

No

Associate Memory – Antibody titer

0.013

No

Associate Memory – Presence of seropositivity

0.021

No

Selective Reminding Test – Antibody titer

0.015

No

Selective Reminding Test – Presence of seropositivity

0.025

No

Digit Span Forward – Antibody titer

0.002

No

Digit Span Forward – Presence of seropositivity

0.003

No

Digit Span Backward – Antibody titer

0.024

No

Digit Span Backward – Presence of seropositivity

0.013

No

Mental Control – Antibody titer

0.007

No

Mental Control - Presence of seropositivity

0.010

No

Letter-Number Sequencing – Antibody titer

0.001

No

Letter-Number Sequencing - Presence of seropositivity

0.001

No

Digit Symbol – Antibody titer

0.010

No

Digit Symbol - Presence of seropositivity

0.006

No

Trails A – Antibody titer

0.020

No

Trails A - Presence of seropositivity

0.023

No

Trails B – Antibody titer

0.018

No

Comparison
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Table 14 Continued
Benjamini-Hochberg
Critical Value

p value less than
critical value

Trails B - Presence of seropositivity

0.016

No

Information – Antibody titer

0.007

No

Information - Presence of seropositivity

0.018

No

Boston Naming – Antibody titer

0.024

No

Boston Naming - Presence of seropositivity

0.015

No

Block Design – Antibody titer

0.019

No

Block Design - Presence of seropositivity

0.014

No

Category Fluency (Animals) – Antibody titer

0.017

No

Category Fluency (Animals) - Presence of seropositivity

0.012

No

Category Fluency (Vegetables) – Antibody titer

0.009

No

Category Fluency (Vegetables) - Presence of seropositivity

0.004

No

Word Fluency – Antibody titer

0.008

No

Word Fluency - Presence of seropositivity

0.011

No

Comparison

seropositive mice had reduced number and volume of beta-amyloid plaques compared to
seronegative mice (Möhle et al., 2016). Additionally, two other studies examining mice models
of AD found less beta-amyloid deposition and less hippocampal neuronal death (Carter, 2013;
Jung et al., 2012). In fact, if these mice studies are similar to what happens in humans, T. gondii
seropositivity would predict inclusion in the control group (those without AD). However, this
evidence of how T. gondii seropositivity affects AD pathology is in mice making definite
conclusions difficult. In sum, our analyses did not support our first hypothesis that T. gondii
seropositivity would significantly predict AD.
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Many more studies have examined the association between T. gondii seropositivity and
cognitive functioning than those that examined AD and T. gondii seropositivity. Our study only
found an association between one processing speed cognitive measure (WAIS-R Digit Symbol)
and T. gondii seropositivity for both AD and control groups combined, specifically that T. gondii
seropositivity may play a role in decreased performance on this neuropsychological test for those
seropositive. Additionally, when we analyzed the AD and control groups separately, we found
an association between the processing speed test of Trailmaking B and the executive functioning
test of Block Design and T. gondii seropositivity, specifically that T. gondii seropositivity may
play a role in decreased performance on these neuropsychological tests for those both with AD
and seropositive. With these analyses, we did control for confounding variables of age, SES,
education level, ethnicity, gender, and ApoE E4 allele status with a statistically stronger method
(propensity score matching) than those used in previous studies. However, for our analyses for
the AD group only, we stress that we did not include an interaction term for group membership
(AD or control group) in the analyses and as such, we cannot compare the AD group results to
the control group results. Additionally, we did not perform a direct statistical test to compare the
effect sizes of the control group and the AD group on each neuropsychological test. Thus, we
cannot conclude that executive functioning is negatively affected due to T. gondii seropositivity
in those with AD but not in those without AD. We can only conclude that in this group of
persons with AD, T. gondii seropositivity seems to have a negative effect on some processing
speed and executive functioning tests (Nieuwenhuis, Forstmann, & Wagenmakers, 2011).
Overall, our finding is largely in line with previous findings of cognitive function and T.
gondii seropositivity which have mainly reported a negative association. Specifically, in regard
to processing speed, other studies have found a negative association between T. gondii
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seropositivity and slower processing speed as a main effect as well as for those of different
ethnicities and with lower income levels (Gale, Brown, Erickson, Berrett, & Hedges, 2014;
Massa et al., 2016; Pearce et al., 2013). Thus, our results in regard to processing speed support
our hypothesis that those T. gondii seropositive would have worse performance on measures of
processing speed. Our study provides some support for previous work performed on processing
speed and T. gondii seropositivity.
For our hypotheses that T. gondii seropositivity would be associated with worse cognitive
functioning for those both seropositive and having AD, we did find a negative association
between T. gondii seropositivity and processing speed and executive functioning in the AD
group. These results supported our hypotheses. However, as mentioned previously, we cannot
determine if on these tests, the T. gondii seropositive participants in the AD group performed
more poorly than the T. gondii seropositive participants in the control group because we did not
directly compare the two groups. To our knowledge, no other studies have directly assessed
cognitive functioning in those with AD who are also T. gondii seropositive. Thus, ours is the
first study to examine the possibility that T. gondii seropositivity may negatively impact
cognition in AD. While other studies examining T. gondii seropositivity and cognition have not
specifically assessed persons with AD, other studies have examined executive functioning in T.
gondii seropositive older adults. Those studies have found overall worse performance on
executive functioning tasks for those seropositive including worse “goal-directed behavior” and
faster declines in executive functioning over time (Beste et al., 2014; Nimgaonkar et al., 2016).
Overall, our results are in line with these previous studies examining non-demented older adults.
It is unclear how T. gondii seropositivity may negatively affect processing speed and
executive functioning abilities. Other studies have found declines in processing speed in older
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adults associated with structural declines in the prefrontal cortex (Eckert, Keren, Roberts,
Calhoun, & Harris, 2010). As mentioned previously, T. gondii cysts have been found by other
studies throughout the brain, making it a possibility that cysts in the prefrontal cortex could be
causing structural changes and thus reducing processing speed. Additionally, researchers have
shown small vessel disease to be associated with reduced processing speed (Eckert et al., 2010).
A secondary effect of small vessel disease is neuroinflammation and recruitment of microglia
and macrophages, which is similar to the inflammatory response seen for T. gondii seropositivity
(Hermes et al., 2008; Rosenberg, 2017). Overall, T. gondii seropositivity may be causing
structural changes as well as increased neuroinflammation which could lead to slower processing
speed for those seropositive. Another possible reason T. gondii seropositivity may decrease
cognitive function is the parasite’s putative effect on dopamine. As mentioned previously,
studies have found both increases and decreases in dopamine in mice brains infected with T.
gondii. However, T. gondii can synthesize L-DOPA and tyrosine and these dopamine precursors
could upset the balance of dopamine in the human brain. For example, Beste et al. (2014)
explained that increased dopamine in the prefrontal cortex can result in increased processing
capacity but make cognitive processing more prone to interference which may make executive
functioning worse. Thus, increased dopamine from T. gondii seropositivity may interfere with
executive functioning in some way. With the prefrontal degeneration seen in AD, increased
dopamine in this area may accentuate the already problematic executive functioning associated
with the prefrontal cortex. Additionally, any structural changes caused by T. gondii cysts in the
prefrontal cortex could also potentially affect executive functioning, as the prefrontal cortex has
been associated with executive functioning in many studies (Funahashi & Andreau, 2013). Thus,
changes in dopamine and/or structure in the prefrontal cortex due to T. gondii seropositivity
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could account for decreases in processing speed and executive functioning seen in our study.
However, because we did not directly assess dopamine, inflammation, or structural changes due
to T. gondii seropositivity, we cannot be certain of any of these proposed mechanisms.
In regard to our other hypotheses, we did not find any other associations between other
cognitive domains (memory, working memory, language functioning, or executive functioning)
and T. gondii seropositivity using either propensity score matching or linear regressions for the
AD and control groups combined. Thus, our analyses did not support our hypotheses of T.
gondii seropositivity predicting worse cognitive functioning for the combined groups in these
other cognitive domains. This is different than other published studies which do find an
association between T. gondii seropositivity and cognitive functioning, most of which find a
negative association between the two. A few studies have not found an association between
cognitive functioning and T. gondii seropositivity (Dickerson et al., 2014; Gulinello et al., 2010).
There could be several factors that would account for the differences in our study from
previous studies. The age, education, socioeconomic status, and ethnicity of participants in
different studies are often significantly different or not reported by the authors. Our study has
the strength of using propensity score matching which matched the participants on these
variables, reducing the influence of these variables on the outcome of analyses. To our
knowledge, no other study has used propensity score matching to control for these potentially
confounding variables when examining the association between T. gondii seropositivity and AD
or the association between T. gondii seropositivity and cognition in humans. However, it is
possible that an association between AD and T. gondii seropositivity or cognition and T. gondii
seropositivity in our study may have been attenuated in some manner. For example, if the
participants in our study were significantly older than those in other studies, it is possible that T.
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gondii seropositive subjects may have died at a higher rate than those seronegative.
Additionally, as lower education and lower SES has been associated with worse cognitive
performance in T. gondii seropositive participants in other studies, the high education level and
higher SES in both the AD and control groups in our study could have protected against
detrimental effects of T. gondii seropositivity, masking associations between AD, cognition, and
T. gondii seropositivity (Gale et al., 2014).
Another possible reason for our study finding different results than other studies may be
the difference in human infection between different strains of T. gondii, as different strains of the
parasite are associated with differences in virulence (Xiao & Yolken, 2016). We did not identify
specific strains of T. gondii in our sample and therefore, could neither control for strain
difference in our sample nor compare the strain composition between our sample and those of
other studies. In addition, host factors likely influence the virulence of T. gondii (Xiao &
Yolken, 2016). We did not evaluate genetic or other host factors in our sample that could affect
the virulence of T. gondii seropositivity on human disease and potentially cognition.
The result of our anti-T. gondii IgM antibody analysis (with only one subject positive for
IgM antibodies in both of the AD and control groups) indicate that the participants in our sample
who were positive for anti-T. gondii antibodies were seropositive for latent but not acute
Toxoplasmosis. The low prevalence of anti-T. gondii IgM antibodies also suggests that in older
adults, AD does not reactivate T. gondii seropositivity, making it unlikely that any association
between T. gondii seropositivity and AD is due to a reactivated infection.

T. GONDII AND COGNITION

83

Strengths and Limitations
Our study has several strengths, particularly its use of PSM as a statistical method. PSM
helps determine causality more so than other statistical methods because it can answer three of
the seven requirements for inferring a causal relationship between two factors (Kazdin, 2003).
First, in this study, we have clear definitions for our outcome and predictor variables. We
defined the outcome, AD, by using standard clinical procedures by WU including: an informant
based semi-structured interview assessing six cognitive domains to give the Clinical Dementia
Rating (CDR) which interview included 18 relevant scales/questionnaires. We defined the
predictor variable by the presence or absence of anti-T. gondii IgG antibodies, an objective
measure. The use of PSM also reduces the chance of selection bias between the control and AD
groups because of the inclusion and matching on several covariates. We included many known
covariates that can affect development of both T. gondii seropositivity including gender,
education, SES, age, ethnicity, and ApoE E4 allele status. Because of the matching procedure of
PSM, those covariates can be ruled out as potential explanations of the relationship (or lack of
relationship) between T. gondii seropositivity and AD. However, there may be other unknown
covariates of both T. gondii seropositivity and AD that were not accounted for in our study.
Additionally, because of the use of PSM, we can have more ability to generalize our results than
previous studies using other statistical methods. However, because we included so few people of
ethnicities other than White in the study along with the higher levels of education and SES in our
sample, generalizations still may be limited. Additionally, we cannot determine the temporal
precedence of T. gondii seropositivity before development of AD because we do not have data of
when each participant became seropositive. Lastly, our results do not show a relationship
statistically between T. gondii seropositivity and development of AD, which relationship is
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required for a causal relationship. Other strengths of the study include the larger sample size
(compared to previous studies), the analysis of many cognitive areas (rather than just one, like in
other studies), and the relative homogeneity of the control and AD group.
We should consider several limitations in the interpretation of our findings. The crosssectional design we used does not allow us to evaluate survivor effects. T. gondii seropositive
subjects with AD may have differentially died before being assessed for T. gondii seropositivity,
making the seroprevalence more equal in the control and AD groups. Also, the cross-sectional
design of our study does not allow us to assess how anti-T. gondii IgG antibodies changed over
time and the effect that may have on AD status and/or cognitive functioning. For example,
Konishi (1989) showed that longitudinally those with higher anti-T. gondii IgG antibody levels
tended to have decreases in antibody levels over time. However, many of the subjects in that
study demonstrated no significant change in antibody titer levels over time and others showed
increases in antibody titers over time making it difficult to say all T. gondii seropositive persons
will have a decrease in antibody titers over time. That being said, a decrease in anti-T. gondii
IgG antibody levels over time could have led to false negatives in our study, resulting in a
misclassification of T. gondii seropositivity status. This could have led to the high rate of no
associations we found in our study because older adults infected before being enrolled in the
study could have a low anti-T. gondii titer due to an anamnestic antibody response (lowering of
antibody titers). However, since our study data are cross-sectional, we cannot directly assess the
length of infection and we also cannot assume that seropositive participants with lower titers are
those with the longest length of T. gondii seropositivity. In addition, we cannot determine
whether any of the subjects had been exposed to T. gondii more than once or whether a previous
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infection had been reactivated at some time. In animals, a reactivation of T. gondii seropositivity
is associated with increases in IgG and IgA antibodies but not IgM antibodies (Singh et al.,
2011).
Importantly, we did not include an interaction term for group (AD or control) when we
performed our analyses using propensity score matching. Due to this, we cannot compare our
results for the AD group to the control group, which is a limitation of our study. Additionally,
we did not assess or include all of the potential risk factors for both AD and development of T.
gondii seropositivity in the models used in our study such as living in foreign countries (outside
the US), having dogs at home, eating raw dried meat, and raising animals (Alvarado-esquivel et
al., 2014). Further, the demographic characteristics of our sample limit the generalizability of
these findings to other groups. For example, very few of our sample were not White (seven
percent in the AD sample and zero percent in the control sample). Given the widespread
distribution and relatively high seroprevalence of T. gondii, and the need to determine potentially
modifiable risk-factors for AD, any association between T. gondii seropositivity and
neurodegeneration needs thorough study, particularly given the neuroinflammation and other
neurological changes associated with T. gondii seropositivity.
Conclusion
In conclusion, despite one previous report showing a possible association between T.
gondii seropositivity and AD, we found no evidence of an association between T. gondii
seropositivity and AD in a cross-sectional study. Additionally, we found limited evidence of a
negative association between processing speed and T. gondii seropositivity. We also found
evidence of negative association between processing speed, executive functioning, and T. gondii
seropositivity in those with AD. Limitations associated with this study, however, indicate that
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the research field needs additional work investigating the possible associations between T. gondii
seropositivity, AD, and cognitive functioning.
Given the continuing emerging evidence that T. gondii seropositivity may play a role in
declining cognition for older adults, employable ideas for prevention of T. gondii infection are
needed, especially for countries with high levels of seroprevalence. As cats are most prevalent
on farms and in rural areas, one possibility for prevention is to vaccinate cats on farms by having
cats ingest a strain of T. gondii oocysts, immunizing the cats without making the cats produce
oocysts. This technique was tested in Illinois in the United States and proved to greatly reduce
the seroprevalence in pigs and mice on the farms tested (Dubey & Jones, 2008). While no
vaccine to T. gondii currently exists for humans, vaccinating cats may help prevent the
transmission of T. gondii. In addition, research into a possible vaccine for humans against T.
gondii may help reduce seroprevalence rates, particularly for those countries with high rates.
Until such a vaccine can be created, other preventative techniques could be promoted by health
departments, healthcare facilities, and even schools and universities. One of the most common
forms of transmission of T. gondii to humans is through contaminated meat and accordingly,
education about properly cooking meat, especially in rural communities could be useful. In
addition, prevalence of T. gondii in wild game and venison is very high in the United States
(Dubey & Jones, 2008). Education for hunters on how to prepare game for human consumption
as well as the proper disposal of game viscera (by burying) may help reduce transmission of T.
gondii due to hunting. This education could be provided by local community centers, places
where hunting guns are sold, or even by shooting ranges. For more populated areas, education
for families about the potential contamination of sandboxes with cat feces may help reduce
infection rates for children. Lastly, as of 2008, there are over 150 million cats in the United
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States (Dubey & Jones, 2008). Increased emphasis on campaigns to spay and neuter cats
(including feral cats) such as efforts by the Best Friends Animal Society, may help contain an
expanding cat population and as a consequence, reduce transmission of T. gondii.
In addition to prevention efforts, more research is needed by the field to expand and
solidify the connections between T. gondii seropositivity and cognition. Important holes in the
current research include a lack of studying potential differences on cognition due to different T.
gondii strains, interactions between T. gondii and different host factors, and use of longitudinal
techniques. There are three main genotypes of T. gondii strains with a fourth atypical strain
(Webster et al., 2013). Very few studies have examined the differences in cognitive effects for
mice due to strain and to our knowledge, no study in humans has examined the possible effect of
T. gondii strain on cognition. Different T. gondii strains may affect humans differently. For
example, some strains have higher levels of expression of tyrosine hydroxylase genes which may
interact differently when encysted in the human brain (Webster et al., 2013). More differences
have been seen genetically between strains which may likely result in differences in how T.
gondii affects cognition in humans. Along with different T. gondii strains, different strains of
mice have been used in many experiments. Worth et al. (2014) point out the importance of
differences in susceptibility to T. gondii between mice strains. Different models of mice, such as
mouse models of AD or other neurological disorders could also be useful for researchers in
elucidating how T. gondii seropositivity affects cognition when combined with different
disorders.
Just as different strains of mice may play a role in T. gondii seropositivity, individual
differences in humans may also affect how seropositivity affects cognition. Human differences
in genetics and immune responses may be of particular interest for researchers. For example, of
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the 432 known genes associated with AD, 27.3% of them are involved in the T. gondii
interactome. This is significantly higher than would be expected by chance according to chisquare analysis. The overlapping genes in T. gondii and AD include genes for amyloid precursor
protein (APP) processing, cholesterol and lipoprotein function, complement and immune-related
genes, and oxidative stress, apoptosis and ubiquitin genes, which are all important genes for both
AD and T. gondii seropositivity (Carter, 2013). Given the genetic overlap between one
neurological disorder and T. gondii, other human neurological disorders may also have similar
genes to T. gondii, which may influence the effect of the parasite on humans. Also, differences
in common genes may protect humans from detrimental effects of T. gondii seropositivity. As
mentioned previously, some studies did not find an effect of T. gondii seropositivity on cognition
or found that seropositivity was associated with better cognition (Gulinello et al., 2010; Stock et
al., 2014). These differences in results may be due to differences in genetic factors that interact
between humans and the parasite, but these factors have yet to be studied by researchers.
Another important individual factor is the differences in the immune response to T. gondii
seropositivity. For example, a few studies have examined the potential interactions between T.
gondii seropositivity, cytokines, and cognition in mice but none, to our knowledge, have
examined this relationship in humans (Hamdani et al., 2015; Mahmoudvand, Sheibani, Shojaee,
et al., 2016). A different immune response by a host, such as more or less neuroinflammation,
may result in different cognitive outcomes.
Finally, an important way to bring clarity and resolution to the research on T. gondii
seropositivity and human cognition would be for research to use longitudinal studies. Currently,
there is debate in the literature on how antibodies to T. gondii change over time and how that
relates to cognition (Flegr et al., 2003). Additionally, researchers know little about how the time
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of infection may differentially affect cognition. For example, does infection in childhood lead to
more detrimental effects on cognition than in adulthood because of the brain’s continuing
development? Or could infection in adulthood lead to more susceptibility to or early onset of
dementia because of increased neuroinflammation? These questions would best be answered
through researchers using longitudinal techniques.
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